<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" data-type="serialArticle" data-version="4.0" id="brb3362" data-xml-lang="en" resource="#">
<head><meta charset="UTF-8" /><title property="http://schema.org/name" lang="en" xml:lang="en">An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis</title><link rel="stylesheet" href="../../styles/tooltip.css" /><link rel="stylesheet" href="../../styles/core.css" /><link rel="stylesheet" href="../../styles/wpa.css" /><link rel="stylesheet" href="../../styles/buttons.css" /><script>
				var stylesPath="../../styles";
				var mathJaxVersion="yes";
				var checkForFF="yes";
				var compType="serialArticle";
			</script><script src="../../styles/jquery-1.11.1.min.js"></script><script src="../../styles/tooltip.js"></script><script src="../../styles/core.js"></script><script type="text/x-mathjax-config">
			    MathJax.Ajax.config.path["Contrib"] = "https://cdn.mathjax.org/mathjax/contrib";
			    MathJax.Hub.Config({
			      "HTML-CSS": {
			        scale: 95,
			        availableFonts:["STIX-Web","TeX"],
			        preferredFont: "STIX-Web",
			        webFont: "STIX-Web",
			        imageFont: "STIX-Web",
			        undefinedFamily: "wmlpua"
			      },
			      "SVG": {
			        scale: 95,
			        font: "STIX-Web",
			        undefinedFamily: "wmlpua"
			      },
				  "menuSettings": {
                  	zoom: "Click"
                  }
                });
			</script></head>
<body prefix="dcterms: http://purl.org/dc/terms/ schema: http://schema.org/ prism: http://prismstandard.org/namespaces/basic/3.0/ pur: http://prismstandard.org/namespaces/pur/3.0/ prov: http://www.w3.org/ns/prov# sa: https://ns.science.ai# skos: http://www.w3.org/2004/02/skos/core# foaf: http://xmlns.com/foaf/0.1/ wbas: https://ontology.wiley.com/Base# wres: https://ontology.wiley.com/Research#" typeof="wbas:ArticleAtom" property="schema:inLanguage" datatype="xsd:language" content="en"><meta property="schema:accessibilityAPI" content="ARIA" /><meta property="schema:accessibilityFeature" content="MathML" /><meta property="schema:accessibilityFeature" content="alternativeText" /><meta property="schema:accessibilityFeature" content="readingOrder" /><meta name="viewport" content="width=device-width" /><header><div class="publicationMeta" data-level="unit"><meta property="wbas:publicationType" resource="https://vocabulary.wiley.com/PublicationType/OriginalArticle" />







</div><div class="contentMeta">

<span class="titleGroup">

</span>
</div></header><article class="displayed-content" data-sections-numbered="no"><header><span class="id" data-type="eLocator" data-value="e00362" property="wbas:eLocator" content="e00362">e00362</span><h1 class="componentTitle"><span class="title" data-type="main" property="schema:name" datatype="rdf:HTML"><span class="RDFa" lang="en" xml:lang="en">An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis</span></span></h1></header><div role="contentinfo">
<section class="creators"><h2 class="title" data-generated_text="yes" data-display="no">Creators</h2><ol><li class="creator" data-affiliation-ref="#brb3362-aff-0001" data-corresponding="yes" data-creator-role="author" id="brb3362-cr-0001" typeof="sa:ContributorRole" resource="info:doi/10.1002/brb3.362/ContribRole/0001" rel="schema:author"><link property="sa:roleAffiliation" href="info:doi/10.1002/brb3.362/brb3362-aff-0001" /><meta property="schema:position" content="1" datatype="xsd:integer" /><div rel="schema:author" resource="info:doi/10.1002/brb3.362/brb3362-cr-0001" typeof="schema:Person"><span class="personName" xml:lang="en" lang="en"><span class="givenNames" property="schema:givenName">Neeta</span> <span class="familyName" property="schema:familyName">Garg</span><span property="schema:name">Neeta Garg</span></span><span class="affiliationRef">1,<span class="correspondingIcon"></span></span><span class="contactDetails"><meta property="schema:email" content="Neeta.Garg@umassmemorial.org" /><a class="email" href="mailto:Neeta.Garg@umassmemorial.org">Neeta.Garg@umassmemorial.org</a></span></div><span class="generated-text">, &#xa0;</span></li><li class="creator" data-affiliation-ref="#brb3362-aff-0002" data-corresponding="yes" data-creator-role="author" id="brb3362-cr-0002" typeof="sa:ContributorRole" resource="info:doi/10.1002/brb3.362/ContribRole/0002" rel="schema:author"><link property="sa:roleAffiliation" href="info:doi/10.1002/brb3.362/brb3362-aff-0002" /><meta property="schema:position" content="2" datatype="xsd:integer" /><div rel="schema:author" resource="info:doi/10.1002/brb3.362/brb3362-cr-0002" typeof="schema:Person"><span class="personName" xml:lang="en" lang="en"><span class="givenNames" property="schema:givenName">Thomas W.</span> <span class="familyName" property="schema:familyName">Smith</span><span property="schema:name">Thomas W. Smith</span></span><span class="affiliationRef">2,<span class="correspondingIcon"></span></span><span class="contactDetails"><meta property="schema:email" content="Thomas.Smith@umassmemorial.org" /><a class="email" href="mailto:Thomas.Smith@umassmemorial.org">Thomas.Smith@umassmemorial.org</a></span></div></li></ol><span rel="sa:contact" resource="info:doi/10.1002/brb3.362/ContactRole/0001" typeof="sa:ContactRole"><meta property="schema:position" content="1" datatype="xsd:integer" /><span property="sa:contact" resource="info:doi/10.1002/brb3.362/brb3362-cr-0001"></span></span><span rel="sa:contact" resource="info:doi/10.1002/brb3.362/ContactRole/0002" typeof="sa:ContactRole"><meta property="schema:position" content="2" datatype="xsd:integer" /><span property="sa:contact" resource="info:doi/10.1002/brb3.362/brb3362-cr-0002"></span></span></section>
<section class="affiliationGroup"><h2 class="title" data-generated_text="yes" data-display="no">Affiliations</h2><ol><li class="affiliation" data-type="organization" id="brb3362-aff-0001" about="info:doi/10.1002/brb3.362/brb3362-aff-0001" typeof="schema:Organization"><span class="affiliationRef">1</span><span property="schema:name" lang="en" xml:lang="en">Department of Neurology, University of Massachusetts Medical School</span><span class="address" resource="info:doi/10.1002/brb3.362/brb3362-aff-0001/address" rel="schema:address" typeof="schema:PostalAddress"><span class="orgDiv" property="wbas:addressDepartment" xml:lang="en" lang="en">Department of Neurology</span><span class="orgName" property="wbas:addressOrganization" xml:lang="en" lang="en">University of Massachusetts Medical School</span><span class="city" property="schema:addressLocality" xml:lang="en" lang="en">Worcester</span><span class="countryPart" property="schema:addressRegion" xml:lang="en" lang="en">Massachusetts</span><span class="postCode" property="schema:postalCode">01655</span><span property="schema:addressCountry" content="US" datatype="dcterms:ISO3166"></span></span></li><li class="affiliation" data-type="organization" id="brb3362-aff-0002" about="info:doi/10.1002/brb3.362/brb3362-aff-0002" typeof="schema:Organization"><span class="affiliationRef">2</span><span property="schema:name" lang="en" xml:lang="en">Department of Pathology, University of Massachusetts Medical School</span><span class="address" resource="info:doi/10.1002/brb3.362/brb3362-aff-0002/address" rel="schema:address" typeof="schema:PostalAddress"><span class="orgDiv" property="wbas:addressDepartment" xml:lang="en" lang="en">Department of Pathology</span><span class="orgName" property="wbas:addressOrganization" xml:lang="en" lang="en">University of Massachusetts Medical School</span><span class="city" property="schema:addressLocality" xml:lang="en" lang="en">Worcester</span><span class="countryPart" property="schema:addressRegion" xml:lang="en" lang="en">Massachusetts</span><span class="postCode" property="schema:postalCode">01655</span><span property="schema:addressCountry" content="US" datatype="dcterms:ISO3166"></span></span></li></ol></section>

<div class="correspondenceTo">
<div class="lineatedText">
<div class="line">
<b>Correspondence</b>
</div>
<div class="line">Neeta Garg, Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA 01655. Tel: +508 334 2527; Fax: +774 442 9122; E&#x2010;mail: <a class="email" href="mailto:Neeta.Garg@umassmemorial.org">Neeta.Garg@umassmemorial.org</a> and</div>
<div class="line">Thomas W. Smith, Department of Pathology, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA 01655. Tel: +508 856 2331; Fax: +508&#x2010;793&#x2010;6110; E&#x2010;mail: <a class="email" href="mailto:Thomas.Smith@umassmemorial.org">Thomas.Smith@umassmemorial.org</a></div></div>
</div><span class="rule"></span>
<section class="abstract" data-type="main" id="brb3362-abs-0001" lang="en" xml:lang="en" rel="wbas:hasAbstract" resource="info:doi/10.1002/brb3.362/abstract/0001" typeof="wbas:Abstract" role="doc-abstract"><meta property="schema:inLanguage" content="en" datatype="xsd:language" /><header class="titleGroup"><h2 class="title" data-type="main">Abstract</h2></header><div class="abstractBody" property="dcterms:description" datatype="rdf:HTML">
<section class="section" id="brb3362-sec-0001"><header class="titleGroup"><h3 class="title" data-type="main">Background</h3></header><p>Multiple sclerosis is an acquired demyelinating disease of the central nervous system. It is the second most common cause of disability in adults in United States after head trauma.</p></section>
<section class="section" id="brb3362-sec-0002"><header class="titleGroup"><h3 class="title" data-type="main">Discussion</h3></header><p>The etiology of <span class="fc">MS</span> is probably multifactorial, related to genetic, environmental, and several other factors. The pathogenesis is not fully understood but is believed to involve T&#x2010;cell&#x2010;mediated inflammation directed against myelin and other related proteins with a possible role for B cells. The McDonald criteria have been proposed and revised over the years to guide the diagnosis of <span class="fc">MS</span> and are based on clinical presentation and magnetic resonance imaging (<span class="fc">MRI</span>) of the brain and spinal cord to establish dissemination in time and space. The treatment of <span class="fc">MS</span> includes disease modification with immunomodulator drugs and symptom management to address the specific symptoms such as fatigue, spasticity, and pain.</p></section>
<section class="section" id="brb3362-sec-0003"><header class="titleGroup"><h3 class="title" data-type="main">Conclusion</h3></header><p>An update on etiology, pathogenesis, diagnosis, and immunomodulatory treatment of <span class="fc">MS</span> is presented.</p></section></div></section>
<section class="abstract" data-type="graphical" id="brb3362-abs-0002" lang="en" xml:lang="en" rel="wbas:hasAbstract" resource="info:doi/10.1002/brb3.362/abstract/0002" typeof="wbas:Abstract"><meta property="schema:inLanguage" content="en" datatype="xsd:language" /><meta property="schema:category" resource="https://vocabulary.wiley.com/PublicationType/AbstractGraphical" /><header class="titleGroup"><h2 class="title" data-generated_text="yes" data-display="no">Graphical Abstract</h2></header><div class="abstractBody" property="dcterms:description" datatype="rdf:HTML">
<p class="split-p" data-p_id="pId-4">Multiple sclerosis is an acquired demyelinating disease of the central nervous system. The etiology of MS is probably multifactorial, related to genetic, environmental, and several other factors. The pathogenesis is not fully understood but is believed to involve T&#x2010;cell&#x2010;mediated inflammation directed against myelin and other related proteins with a possible role for B cells. The treatment of MS includes disease modification with immunomodulator drugs and symptom management to address the specific symptoms such as fatigue, spasticity, pain, etc. An update on etiology, immunopathogenesis, diagnosis, and treatment of MS is presented.</p>
<div class="split-p" data-p_id="pId-4">
<figure class="blockFixed" data-type="graphic" id="brb3362-blkfxd-0001"><div class="mediaResourceGroup">
<img class="mediaResource" src="image_n/brb3362-toc-0001.png" data-href="urn:x-wiley:21623279:brb3362:brb3362-toc-0001" alt="image" />


</div></figure>
</div></div></section>
<section class="keywordGroup" data-type="author" lang="en" xml:lang="en"><h2 class="title" data-generated_text="yes">Keywords</h2><ul><li class="keyword" id="brb3362-kwd-0001" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">Demyelination</span></li><li class="keyword" id="brb3362-kwd-0002" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">diagnosis</span></li><li class="keyword" id="brb3362-kwd-0003" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">etiology</span></li><li class="keyword" id="brb3362-kwd-0004" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">immunomodulator</span></li><li class="keyword" id="brb3362-kwd-0005" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">multiple sclerosis</span></li><li class="keyword" id="brb3362-kwd-0006" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">pathogenesis</span></li><li class="keyword" id="brb3362-kwd-0007" property="schema:keywords" datatype="rdf:HTML"><span class="RDFa">treatment</span></li></ul></section></div><section class="section" id="brb3362-sec-0004" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Introduction</h2></header><p>Multiple sclerosis is an autoimmune inflammatory disorder of CNS of unknown etiology, characterized by demyelination and variable degrees of axonal loss. The disease affects mostly young women (between ages 20 and 40&#xa0;years) and is one of leading causes of disability in young adults in United States (Orton et&#xa0;al. <span class="link" data-href="#brb3362-bib-0081" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0081" aria-label="Orton, 2006"><span class="generated-labeling">2006</span></a></span>; Kister et&#xa0;al. <span class="link" data-href="#brb3362-bib-0058" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0058" aria-label="Kister, 2013"><span class="generated-labeling">2013</span></a></span>). Its prevalence in the United States is about 400,000 and over two million people are affected worldwide with an expected increase in the number of cases in future (Weinshenker <span class="link" data-href="#brb3362-bib-0101" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0101" aria-label="Weinshenker, 1996"><span class="generated-labeling">1996</span></a></span>; Mayr et&#xa0;al. <span class="link" data-href="#brb3362-bib-0069" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0069" aria-label="Mayr, 2003"><span class="generated-labeling">2003</span></a></span>). The disease appears to be more common in northern hemisphere and there is some genetic susceptibility as well in individuals of Scandinavian or northern European ancestry (Williams et&#xa0;al. <span class="link" data-href="#brb3362-bib-0104" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0104" aria-label="Williams, 1995"><span class="generated-labeling">1995</span></a></span>; Compston and Coles <span class="link" data-href="#brb3362-bib-0022" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0022" aria-label="Compston, 2008"><span class="generated-labeling">2008</span></a></span>). The etiology although unknown presumably involves interaction between genetic, environmental, and other factors triggering an aberrant autoimmune attack resulting in damage to myelin and axons (Bruck and Stadelmann <span class="link" data-href="#brb3362-bib-0015" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0015" aria-label="Bruck, 2005"><span class="generated-labeling">2005</span></a></span>). The course of MS can be variable with a significant proportion of patients experiencing some progression following the initial relapsing remitting phase leading to significant disability (Weinshenker et&#xa0;al. <span class="link" data-href="#brb3362-bib-0102" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0102" aria-label="Weinshenker, 1989"><span class="generated-labeling">1989</span></a></span>; Lublin and Reingold <span class="link" data-href="#brb3362-bib-0064" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0064" aria-label="Lublin, 1996"><span class="generated-labeling">1996</span></a></span>). Much progress has been made in the past two decades in treating MS with the advent of effective immunomodulatory therapies which can potentially slow down the progression and alter the disease course.</p></section><section class="section" id="brb3362-sec-0005" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Etiology</h2></header><p>The etiology of MS remains unknown; however, it is believed to be caused by immune dysregulation triggered by genetic and environmental factors (Ascherio and Munger <span class="link" data-href="#brb3362-bib-0004" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0004" aria-label="Ascherio, 2007a"><span class="generated-labeling">2007a</span></a></span>,<span class="link" data-href="#brb3362-bib-0005" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0005" aria-label="Ascherio, 2007b">b</a></span>). Although MS is not an inherited disease, there is a strong genetic component to its etiology as evidenced by clustering of MS cases within families. The risk of MS among first&#x2010;degree relatives of MS patients is 10&#x2013;50 times higher than the general population (absolute risk 2&#x2013;5%); the concordance rate in monzygotic twins is about one&#x2010;third (Weinshenker <span class="link" data-href="#brb3362-bib-0101" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0101" aria-label="Weinshenker, 1996"><span class="generated-labeling">1996</span></a></span>; Kantarci <span class="link" data-href="#brb3362-bib-0054" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0054" aria-label="Kantarci, 2008"><span class="generated-labeling">2008</span></a></span>). Linkage analysis studies have revealed several gene loci as risk factors, with the major histocompatibility complex (MHC) HLA DR15/DQ6 allele being the strongest one (Barcellos et&#xa0;al. <span class="link" data-href="#brb3362-bib-0008" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0008" aria-label="Barcellos, 2003"><span class="generated-labeling">2003</span></a></span>; Sawcer et&#xa0;al. <span class="link" data-href="#brb3362-bib-0091" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0091" aria-label="Sawcer, 2011"><span class="generated-labeling">2011</span></a></span>). More recently, alleles of interleukin&#x2010;2 receptor alpha gene (IL2RA) and interleukin&#x2010;7 receptor alpha gene (IL7RA) have also been identified as inheritable risk factors (Hafler et&#xa0;al. <span class="link" data-href="#brb3362-bib-0047" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0047" aria-label="Hafler, 2007"><span class="generated-labeling">2007</span></a></span>; Sawcer et&#xa0;al. <span class="link" data-href="#brb3362-bib-0091" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0091" aria-label="Sawcer, 2011"><span class="generated-labeling">2011</span></a></span>). However, most of the genetic factors underlying susceptibility still remain to be defined. Furthermore, genetic susceptibility does not fully explain the changes in MS risk that occur with migration suggesting a likely role for environmental factors.</p><p>Among environmental factors, Epstein&#x2010;Barr virus (EBV) infection and vitamin D deficiency have been extensively studied and strongly linked to MS risk (Ascherio and Munger <span class="link" data-href="#brb3362-bib-0004" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0004" aria-label="Ascherio, 2007a"><span class="generated-labeling">2007a</span></a></span>,<span class="link" data-href="#brb3362-bib-0005" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0005" aria-label="Ascherio, 2007b">b</a></span>) MS is prevalent in geographic areas farther away from the equator (Simpson et&#xa0;al. <span class="link" data-href="#brb3362-bib-0093" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0093" aria-label="Simpson, 2011"><span class="generated-labeling">2011</span></a></span>). Low vitamin D levels from reduced sun exposure may be a factor contributing to increased susceptibility to MS in these regions (Ascherio and Munger <span class="link" data-href="#brb3362-bib-0005" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0005" aria-label="Ascherio, 2007b"><span class="generated-labeling">2007b</span></a></span>; Correale et&#xa0;al. <span class="link" data-href="#brb3362-bib-0025" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0025" aria-label="Correale, 2009"><span class="generated-labeling">2009</span></a></span>; Ascherio et&#xa0;al. <span class="link" data-href="#brb3362-bib-0006" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0006" aria-label="Ascherio, 2010"><span class="generated-labeling">2010</span></a></span>). Studies have suggested that higher levels of vitamin D have a possible protective role in certain susceptible patient populations (Munger et&#xa0;al. <span class="link" data-href="#brb3362-bib-0074" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0074" aria-label="Munger, 2004"><span class="generated-labeling">2004</span></a></span>, <span class="link" data-href="#brb3362-bib-0075" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0075" aria-label="Munger, 2006"><span class="generated-labeling">2006</span></a></span>). The risk of developing MS is approximately 15&#x2010;fold higher among individuals with a history of EBV infection in childhood and about 30&#x2010;fold higher among those infected with EBV in adolescence or later in life (Ascherio <span class="link" data-href="#brb3362-bib-0003" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0003" aria-label="Ascherio, 2013"><span class="generated-labeling">2013</span></a></span>). However, the difference in the risk of MS among migrants from high to low MS prevalence areas suggests that other infectious or noninfectious factors in addition to EBV may be involved (Ascherio and Munger <span class="link" data-href="#brb3362-bib-0004" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0004" aria-label="Ascherio, 2007a"><span class="generated-labeling">2007a</span></a></span>,<span class="link" data-href="#brb3362-bib-0005" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0005" aria-label="Ascherio, 2007b">b</a></span>). The &#x201c;hygiene hypothesis,&#x201d; supported by many epidemiological observations, suggests that improved sanitation and reduced childhood infections in developed countries may account for the increased rates of autoimmune diseases (T&#x2010;helper 1 mediated) and allergy (T&#x2010;helper 2 mediated) (Conradi et&#xa0;al. <span class="link" data-href="#brb3362-bib-0024" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0024" aria-label="Conradi, 2011"><span class="generated-labeling">2011</span></a></span>). However, this hypothesis does not explain the higher MS prevalence in rural compared to urban areas (with expected improved sanitation) reported in some studies (Sotgiu et&#xa0;al. <span class="link" data-href="#brb3362-bib-0095" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0095" aria-label="Sotgiu, 2003"><span class="generated-labeling">2003</span></a></span>).</p><p>Cigarette smoking has also been proposed at a potential environmental risk factor with several studies reporting an association between smoking and MS risk and disease activity (Wingerchuk <span class="link" data-href="#brb3362-bib-0105" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0105" aria-label="Wingerchuk, 2012"><span class="generated-labeling">2012</span></a></span>). The odds ratio for developing MS is approximately 1.5 for smokers compared with nonsmokers (Wingerchuk <span class="link" data-href="#brb3362-bib-0105" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0105" aria-label="Wingerchuk, 2012"><span class="generated-labeling">2012</span></a></span>; Fragoso <span class="link" data-href="#brb3362-bib-0036" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0036" aria-label="Fragoso, 2014"><span class="generated-labeling">2014</span></a></span>). As with other risk factors, smoking appears to influence the MS susceptibility in conjunction with the genetic and other environmental factors.</p><p>There is no specific diet associated with increased risk of MS. The role of dietary factors appears to be complex and related to the influence of multiple dietary components including vitamin A and D, salt, omega&#x2010;3&#x2010;unsaturated fatty acid, and polyphenol on immune regulation. Some recent reports have suggested that salt modulates the differentiation of human and mouse Th17 cells (Kleinewietfeld et&#xa0;al. <span class="link" data-href="#brb3362-bib-0059" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0059" aria-label="Kleinewietfeld, 2013"><span class="generated-labeling">2013</span></a></span>; Wu et&#xa0;al. <span class="link" data-href="#brb3362-bib-0107" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0107" aria-label="Wu, 2013"><span class="generated-labeling">2013</span></a></span>). A more aggressive course of experimental autoimmune encephalomyelitis (EAE) was observed in mice fed a high sodium diet. In a small observational study, higher sodium intake was associated with increased clinical and radiological disease activity in patients with MS (Farez et&#xa0;al. <span class="link" data-href="#brb3362-bib-0029" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0029" aria-label="Farez, 2015"><span class="generated-labeling">2015</span></a></span>).</p><p>The potential risk factors for MS are listed in Table&#xa0;<span class="link" data-href="#brb3362-tbl-0001"><a class="linkAnchor" href="#brb3362-tbl-0001"><span class="generated-labeling">1</span></a></span>.</p><figure class="tabular" data-copyright="John Wiley &amp; Sons, Ltd" id="brb3362-tbl-0001"><figcaption>
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="tabular" data-generated_text="yes"><span class="object-name-title">Table </span><span class="generated-labeling">1</span></span><span class="title" data-type="main">Potential risk factors for multiple sclerosis</span></header></figcaption><table class="topbot pgwide" data-rowsep="0" data-colsep="0" data-pgwide="1" data-tgroup_cols="1"><colgroup><col data-colname="col1" data-colnum="1" data-colsep="0" /></colgroup><tbody><tr><td class="align-left" data-colname="col1" data-align="left">Female gender</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Caucasian race</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Genetic</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">HLA DR15/DQ6, IL2RA and IL7RA alleles</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Infections</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Epstein&#x2013;Barr virus (EBV) infection</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Temperate climate</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Low vitamin D level</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Lack of sunlight exposure</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Cigarette smoking</td></tr></tbody></table></figure></section><section class="section" id="brb3362-sec-0006" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Immunopathogenes</h2></header><p>The pathogenesis of MS involves immune attack against CNS antigens mediated through activated CD4+ myelin&#x2010;reactive T cells with a possible contribution by B cells. Much of our understanding of immunopathogenesis of MS is derived from the study of experimental autoimmune encephalomyelitis (EAE), an animal model of CNS inflammatory demyelination that can be induced by peripheral immunization with myelin protein components. EAE shares many of the histologic features of MS including active demyelination, oligodendrocyte and axonal loss, all of which are presumably mediated by myelin specific T cells (Yong <span class="link" data-href="#brb3362-bib-0109" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0109" aria-label="Yong, 2004"><span class="generated-labeling">2004</span></a></span>; Gold et&#xa0;al. <span class="link" data-href="#brb3362-bib-0042" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0042" aria-label="Gold, 2006"><span class="generated-labeling">2006</span></a></span>). The immunopathogenesis of MS is thought to involve a breach of self&#x2010;tolerance toward myelin and other CNS antigens resulting in persistent peripheral activation of autoreactive T cells (Hafler et&#xa0;al. <span class="link" data-href="#brb3362-bib-0046" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0046" aria-label="Hafler, 2005"><span class="generated-labeling">2005</span></a></span>; Selter and Hemmer <span class="link" data-href="#brb3362-bib-0092" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0092" aria-label="Selter, 2013"><span class="generated-labeling">2013</span></a></span>). In a genetically susceptible individual, this loss of self&#x2010;tolerance may be triggered by an environmental antigen, presumably an infectious agent such as a virus. The infection could cause bystander activation of T cells or result in release of autoantigens due to cellular damage, which can then lead to activation of T cells by cross reactivity between an endogenous protein (e.g., myelin basic protein) and the pathogenic exogenous protein (viral or bacterial antigen), a process known as molecular mimicry (Fujinami and Oldstone <span class="link" data-href="#brb3362-bib-0039" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0039" aria-label="Fujinami, 1985"><span class="generated-labeling">1985</span></a></span>; Wucherpfennig and Strominger <span class="link" data-href="#brb3362-bib-0108" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0108" aria-label="Wucherpfennig, 1995"><span class="generated-labeling">1995</span></a></span>; Aichele et&#xa0;al. <span class="link" data-href="#brb3362-bib-0002" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0002" aria-label="Aichele, 1996"><span class="generated-labeling">1996</span></a></span>; Gran et&#xa0;al. <span class="link" data-href="#brb3362-bib-0044" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0044" aria-label="Gran, 1999"><span class="generated-labeling">1999</span></a></span>; O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0077" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0077" aria-label="O'Connor, 2001"><span class="generated-labeling">2001</span></a></span>).</p><p>As depicted in Figure&#xa0;<span class="link" data-href="#brb3362-fig-0001"><a class="linkAnchor" href="#brb3362-fig-0001"><span class="generated-labeling">1</span></a></span>, once activated in the periphery, myelin&#x2010;reactive T cells are able to migrate across the blood&#x2013;brain barrier (BBB). The transmigration process involves interaction between very late antigen&#x2010;4 (VLA&#x2010;4) present on T lymphocytes and the vascular cell adhesion molecule&#x2010;1 (VCAM&#x2010;1) expressed on capillary endothelial cells; this process is facilitated by expression and upregulation of various adhesion molecules, chemokines, and matrix metalloproteinases (MMPs) (Yong <span class="link" data-href="#brb3362-bib-0109" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0109" aria-label="Yong, 2004"><span class="generated-labeling">2004</span></a></span>; Gold and Wolinsky <span class="link" data-href="#brb3362-bib-0041" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0041" aria-label="Gold, 2011"><span class="generated-labeling">2011</span></a></span>). After entering the CNS, the autoreactive peripherally activated T cells can be reactivated upon encountering the autoantigenic peptides within the brain parenchyma in the context of MHC class II molecules expressed by local antigen presenting cells (dendritic cells, macrophages, and B cells) triggering an inflammatory cascade leading to release of cytokines and chemokines, recruitment of additional inflammatory cells including T cells, monocytes, and B cells and persistent activation of microglia and macrophages resulting in myelin damage (Hemmer et&#xa0;al. <span class="link" data-href="#brb3362-bib-0049" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0049" aria-label="Hemmer, 2002"><span class="generated-labeling">2002</span></a></span>; Frohman et&#xa0;al. <span class="link" data-href="#brb3362-bib-0038" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0038" aria-label="Frohman, 2006"><span class="generated-labeling">2006</span></a></span>; Inglese <span class="link" data-href="#brb3362-bib-0053" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0053" aria-label="Inglese, 2006"><span class="generated-labeling">2006</span></a></span>). The local inflammation and demyelination results in exposure of sequestered myelin autoantigens providing an additional target for self&#x2010;reactive T cells, a phenomenon called &#x201c;epitope spreading&#x201d; (Miller et&#xa0;al. <span class="link" data-href="#brb3362-bib-0071" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0071" aria-label="Miller, 1997"><span class="generated-labeling">1997</span></a></span>). Activation of resident CNS glial cells (such as microglia) results in persistent inflammation even in absence of further infiltration of exogenous inflammatory cells (O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0077" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0077" aria-label="O'Connor, 2001"><span class="generated-labeling">2001</span></a></span>). The evidence based on animal studies suggests that CD4<sup>+</sup> T&#x2010;helper 1 (T<sub>H</sub>1) cells which release proinflammatory cytokines such as interferon&#x2010;gamma, interleukin&#x2010;2 (IL&#x2010;2), and tumor necrosis factor&#x2010;<i>&#x3b1;</i> (TNF&#x2010;<i>&#x3b1;</i>) are the key players in mediating inflammation in MS with some role for the novel CD4<sup>+</sup> T&#x2010;helper&#x2010;17 (T<sub>H</sub>17) cell subset which secretes IL&#x2010;17 (O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0077" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0077" aria-label="O'Connor, 2001"><span class="generated-labeling">2001</span></a></span>; Selter and Hemmer <span class="link" data-href="#brb3362-bib-0092" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0092" aria-label="Selter, 2013"><span class="generated-labeling">2013</span></a></span>). The CD4<sup>+</sup> T&#x2010;helper 2 (T<sub>H</sub>2) cells, which secret interleukins 4, 5, and 10 are believed to have a counter regulatory role limiting the T<sub>H</sub>1&#x2010;cell&#x2010;mediated injury (Tzartos et&#xa0;al. <span class="link" data-href="#brb3362-bib-0099" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0099" aria-label="Tzartos, 2008"><span class="generated-labeling">2008</span></a></span>). The T<sub>H</sub>1/T<sub>H</sub>2 paradigm is more apparent in EAE; in MS, indirect evidence exists for a predominant role of Th1 cells based on the success of therapies that shift the cytokine profile away from Th1 toward Th2. CD8+ T cells are believed to be involved as well and can induce axonal pathology by direct injury to MHC I/antigen expressing cells such as neurons and oligodendrocytes (Batoulis et&#xa0;al. <span class="link" data-href="#brb3362-bib-0011" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0011" aria-label="Batoulis, 2010"><span class="generated-labeling">2010</span></a></span>). The contribution of B cells to MS pathogenesis (possibly through autoantibody secretion and antigen presentation to T cells) has recently been recognized and is supported by observed pathologic heterogeneity of MS lesions, the presence of meningeal inflammation and B&#x2010;cell follicle&#x2010;like structures adjacent to subpial cortical lesions, and the success of B&#x2010;cell&#x2010;based immunotherapies (O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0077" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0077" aria-label="O'Connor, 2001"><span class="generated-labeling">2001</span></a></span>; Batoulis et&#xa0;al. <span class="link" data-href="#brb3362-bib-0011" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0011" aria-label="Batoulis, 2010"><span class="generated-labeling">2010</span></a></span>; Naismith et&#xa0;al. <span class="link" data-href="#brb3362-bib-0076" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0076" aria-label="Naismith, 2010"><span class="generated-labeling">2010</span></a></span>).</p><figure class="figure" id="brb3362-fig-0001"><div class="mediaResourceGroup">
<img class="mediaResource" src="image_n/brb3362-fig-0001.png" data-href="urn:x-wiley:21623279:media:brb3362:brb3362-fig-0001" alt="image" />



</div><figcaption class="caption-titled">
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="figure" data-generated_text="yes"><span class="object-name-title">Figure </span><span class="generated-labeling">1</span></span></header>Immunopathogenic mechanisms in <span class="fc">MS</span> and proposed targets of different disease modifying therapies.</figcaption></figure><p>Although demyelination is the hallmark of MS pathology, early axonal injury and axonal loss also occur and may drive disability progression (Trapp et&#xa0;al. <span class="link" data-href="#brb3362-bib-0098" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0098" aria-label="Trapp, 1998"><span class="generated-labeling">1998</span></a></span>). The exact mechanism(s) of both myelin and axonal injury are not completely understood, but are likely to include both direct injury to myelin and oligodendrocytes, and axons by CD4+ and CD8+ T lymphocytes, activated microglia/macrophages, and/or antibody and complement as well as the indirect effects of proinflammatory cytokines such as IL&#x2010;1beta, TNF&#x2010;<i>&#x3b1;</i>, nitric oxide, and MMPs (Lucchinetti et&#xa0;al. <span class="link" data-href="#brb3362-bib-0066" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0066" aria-label="Lucchinetti, 2000"><span class="generated-labeling">2000</span></a></span>; Hemmer et&#xa0;al. <span class="link" data-href="#brb3362-bib-0049" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0049" aria-label="Hemmer, 2002"><span class="generated-labeling">2002</span></a></span>; Gold and Wolinsky <span class="link" data-href="#brb3362-bib-0041" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0041" aria-label="Gold, 2011"><span class="generated-labeling">2011</span></a></span>). Meningeal inflammatory infiltrates reported in association with subpial cortical lesions may contribute to cortical inflammation and disability in some cases (Howell et&#xa0;al. <span class="link" data-href="#brb3362-bib-0050" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0050" aria-label="Howell, 2011"><span class="generated-labeling">2011</span></a></span>; Lucchinetti et&#xa0;al. <span class="link" data-href="#brb3362-bib-0068" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0068" aria-label="Lucchinetti, 2011"><span class="generated-labeling">2011</span></a></span>).</p></section><section class="section" id="brb3362-sec-0007" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Pathology</h2></header><p>The MS plaques or lesions are focal areas of demyelination associated with variable inflammation and axonal loss that predominantly affect the white matter of the brain, spinal cord, and optic nerves but can also involve the cerebral cortex including subpial regions (Sobel and Moore <span class="link" data-href="#brb3362-bib-0094" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0094" aria-label="Sobel, 2008"><span class="generated-labeling">2008</span></a></span>; Popescu and Lucchinetti <span class="link" data-href="#brb3362-bib-0085" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0085" aria-label="Popescu, 2012"><span class="generated-labeling">2012</span></a></span>). The inflammatory infiltrates associated with plaques consist of activated T cells (predominantly CD8+ with variable presence of CD4+ cells), activated macrophages/microglia, plasma cells, and B cells (Hauser et&#xa0;al. <span class="link" data-href="#brb3362-bib-0048" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0048" aria-label="Hauser, 1986"><span class="generated-labeling">1986</span></a></span>; O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0077" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0077" aria-label="O'Connor, 2001"><span class="generated-labeling">2001</span></a></span>). MS plaques can be further classified histologically as active, chronic, and remyelinated. Active lesions are common in relapsing remitting MS and are characterized by myelin degradation (with relative axonal preservation), macrophage infiltration, reactive astrocytes, and perivascular and parenchymal inflammation (Bruck et&#xa0;al. <span class="link" data-href="#brb3362-bib-0016" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0016" aria-label="Bruck, 1995"><span class="generated-labeling">1995</span></a></span>; Frischer et&#xa0;al. <span class="link" data-href="#brb3362-bib-0037" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0037" aria-label="Frischer, 2009"><span class="generated-labeling">2009</span></a></span>). Chronic or inactive plaques are more often seen in patients with progressive disease and are associated with more extensive demyelination, often with marked axonal depletion, loss of oligodendrocytes, and relative absence of active inflammation (Prineas et&#xa0;al. <span class="link" data-href="#brb3362-bib-0086" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0086" aria-label="Prineas, 2001"><span class="generated-labeling">2001</span></a></span>; Sobel and Moore <span class="link" data-href="#brb3362-bib-0094" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0094" aria-label="Sobel, 2008"><span class="generated-labeling">2008</span></a></span>; Popescu and Lucchinetti <span class="link" data-href="#brb3362-bib-0085" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0085" aria-label="Popescu, 2012"><span class="generated-labeling">2012</span></a></span>). Remyelinated plaques are seen within or more often at the margins of active plaques and contain thinly myelinated axons and often increased numbers of oligodendrocyte precursor cells (Bruck et&#xa0;al. <span class="link" data-href="#brb3362-bib-0016" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0016" aria-label="Bruck, 1995"><span class="generated-labeling">1995</span></a></span>; Popescu and Lucchinetti <span class="link" data-href="#brb3362-bib-0085" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0085" aria-label="Popescu, 2012"><span class="generated-labeling">2012</span></a></span>). &#x201c;Shadow plaques&#x201d; are lesions that show more diffuse (but still incomplete) remyelination and are seen in patients with relapsing and progressive disease (Barkhof et&#xa0;al. <span class="link" data-href="#brb3362-bib-0009" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0009" aria-label="Barkhof, 2003"><span class="generated-labeling">2003</span></a></span>). The presence of cortical demyelination and axonal loss has been increasingly recognized in early MS (Trapp et&#xa0;al. <span class="link" data-href="#brb3362-bib-0098" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0098" aria-label="Trapp, 1998"><span class="generated-labeling">1998</span></a></span>; Cifelli et&#xa0;al. <span class="link" data-href="#brb3362-bib-0020" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0020" aria-label="Cifelli, 2002"><span class="generated-labeling">2002</span></a></span>). Lucchinetti and colleagues have described four distinct immmopathological patterns (pattern I with macrophage and T&#x2010;cell predominance, II with additional immunoglobulin and complement deposition, III with apoptotic oligodendrocyte loss, and the rare type IV pattern with nonapoptotic death of oligodendrocytes) in active MS lesions, suggesting that there may be pathological heterogeneity among MS patients (Lucchinetti et&#xa0;al. <span class="link" data-href="#brb3362-bib-0066" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0066" aria-label="Lucchinetti, 2000"><span class="generated-labeling">2000</span></a></span>). However, the observed pathologic heterogeneity may not be exclusive to a subset of MS patients and is probably related to the stage of disease in a given patient (Barnett and Prineas <span class="link" data-href="#brb3362-bib-0010" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0010" aria-label="Barnett, 2004"><span class="generated-labeling">2004</span></a></span>). Cortical involvement can occur in MS and may reflect either the presence of cortical demyelination or actual neuronal loss. Within the cortex, three distinct lesion types have been described based on the location of the plaques: subpial, intracortical, and leukocortical (Bogdan et&#xa0;al. <span class="link" data-href="#brb3362-bib-0014" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0014" aria-label="Bogdan, 2013"><span class="generated-labeling">2013</span></a></span>). Cortical lesions seen in early MS are usually highly inflammatory and correlate with cognitive impairment (Geurts and Barkhof <span class="link" data-href="#brb3362-bib-0040" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0040" aria-label="Geurts, 2008"><span class="generated-labeling">2008</span></a></span>; Lucchinetti et&#xa0;al. <span class="link" data-href="#brb3362-bib-0068" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0068" aria-label="Lucchinetti, 2011"><span class="generated-labeling">2011</span></a></span>).</p></section><section class="section" id="brb3362-sec-0008" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Clinical Presentation and Diagnosis</h2></header><p>The clinical symptoms and signs of MS are variable and may result from involvement of sensory, motor, visual, and brainstem pathways. The majority of patients with MS initially present with relapsing remitting episodes of new or recurrent neurological symptoms. The first clinical event in these patients, termed clinically isolated syndrome (CIS), can be optic neuritis, incomplete myelitis, or brainstem syndrome (Miller et&#xa0;al. <span class="link" data-href="#brb3362-bib-0073" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0073" aria-label="Miller, 2005"><span class="generated-labeling">2005</span></a></span>). The presence of classic demyelination lesions on baseline brain or spinal cord MRI is the most important predictor of having a second relapse in CIS patients (Filippi et&#xa0;al. <span class="link" data-href="#brb3362-bib-0031" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0031" aria-label="Filippi, 1994"><span class="generated-labeling">1994</span></a></span>). The presence of cerebrospinal fluid (CSF) abnormalities (positive oligoclonal bands) may have additional prognostic value in patients with CIS and positive brain MRI (Miller et&#xa0;al. <span class="link" data-href="#brb3362-bib-0073" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0073" aria-label="Miller, 2005"><span class="generated-labeling">2005</span></a></span>; Awad et&#xa0;al. <span class="link" data-href="#brb3362-bib-0007" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0007" aria-label="Awad, 2010"><span class="generated-labeling">2010</span></a></span>). A variable proportion of patients with relapsing remitting MS (25&#x2013;40%) develop secondary progressive disease over time with progressive accumulation of disability with infrequent or no relapses (Lublin and Reingold <span class="link" data-href="#brb3362-bib-0064" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0064" aria-label="Lublin, 1996"><span class="generated-labeling">1996</span></a></span>). Primary progressive MS (seen in approximately 10&#x2013;15% patients) is defined by progressive accumulation of disability from the onset with no or minor relapses and typically presents with a progressive myelopathy with an older age of onset and involving a higher proportion of men (Miller and Leary <span class="link" data-href="#brb3362-bib-0070" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0070" aria-label="Miller, 2007"><span class="generated-labeling">2007</span></a></span>). Both primary and secondary progressive MS share some clinical and imaging features and are now considered to be part of the progressive disease spectrum (Lublin and Reingold <span class="link" data-href="#brb3362-bib-0064" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0064" aria-label="Lublin, 1996"><span class="generated-labeling">1996</span></a></span>; Ingle et&#xa0;al. <span class="link" data-href="#brb3362-bib-0052" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0052" aria-label="Ingle, 2005"><span class="generated-labeling">2005</span></a></span>; Lublin et&#xa0;al. <span class="link" data-href="#brb3362-bib-0065" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0065" aria-label="Lublin, 2014"><span class="generated-labeling">2014</span></a></span>). The progressive relapsing form of MS with worsening disability from onset and clear acute relapses with or without full recovery is now considered to be progressive disease with disease activity (Lublin et&#xa0;al. <span class="link" data-href="#brb3362-bib-0065" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0065" aria-label="Lublin, 2014"><span class="generated-labeling">2014</span></a></span>).</p><p>There is no single diagnostic test for MS and the diagnosis is usually based on the clinical presentation, supported by neuroimaging and in some cases by CSF analysis (to look for inflammatory markers oligoclonal bands and/or elevated IgG index) and evoked potential studies (to look for clinically silent lesion in visual, brainstem, or spinal cord pathways). CSF inflammatory markers are present in up to 85% patients with MS (Link and Huang <span class="link" data-href="#brb3362-bib-0062" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0062" aria-label="Link, 2006"><span class="generated-labeling">2006</span></a></span>); IgG index is less sensitive and specific than oligoclonal bands Awad et&#xa0;al. <span class="link" data-href="#brb3362-bib-0007" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0007" aria-label="Awad, 2010"><span class="generated-labeling">2010</span></a></span>). There have been several proposed diagnostic criteria incorporating the clinical and ancillary data, the most commonly used one is the McDonald criteria initially proposed in 2001 and revised in 2005 and most recently in 2011 (Polman et&#xa0;al. <span class="link" data-href="#brb3362-bib-0084" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0084" aria-label="Polman, 2011"><span class="generated-labeling">2011</span></a></span>). The basic concept behind these criteria is demonstration of dissemination in time (DIT) and space using the clinical and/or MRI data. A detailed discussion of McDonald criteria is beyond the scope of this review; in summary, the definitive diagnosis of MS requires &#x2265;2 attacks or objective clinical evidence of &#x2265; 2 lesions or objective clinical evidence of 1 lesion with historical evidence of a prior attack. With one clinical attack, DIT can be demonstrated by presence of asymptomatic gadolinium&#x2010;enhancing and nonenhancing lesions at any time or by presence of new lesions on a follow&#x2010;up scan obtained anytime after the initial symptom onset or the simultaneous (see Table&#xa0;<span class="link" data-href="#brb3362-tbl-0002"><a class="linkAnchor" href="#brb3362-tbl-0002"><span class="generated-labeling">2</span></a></span>). Dissemination in space (DIS) in a patient with two clinical attacks but objective evidence of one lesion can be demonstrated by using the MRI criteria detailed in Table&#xa0;<span class="link" data-href="#brb3362-tbl-0003"><a class="linkAnchor" href="#brb3362-tbl-0003"><span class="generated-labeling">3</span></a></span>. The criteria for primary progressive MS include 1&#xa0;year of disease progression plus two of the following criteria: a. evidence of DIS in brain, b. DIS in spinal cord (&#x2265; 2 T2 lesions in the cord), c. positive CSF oligoclonal bands and/or elevated IgG index.</p><figure class="tabular" data-copyright="John Wiley &amp; Sons, Ltd" id="brb3362-tbl-0002"><figcaption>
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="tabular" data-generated_text="yes"><span class="object-name-title">Table </span><span class="generated-labeling">2</span></span><span class="title" data-type="main">McDonald MRI criteria for demonstration of DIT (Polman et&#xa0;al. <span class="link" data-href="#brb3362-bib-0084" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0084" aria-label="Polman, 2011"><span class="generated-labeling">2011</span></a></span>)</span></header></figcaption><table class="topbot pgwide" data-rowsep="0" data-colsep="0" data-pgwide="1" data-tgroup_cols="1"><colgroup><col data-colname="col1" data-colnum="1" data-colsep="0" /></colgroup><thead class="valign-top"><tr data-rowsep="1"><th class="eR align-left" data-colname="col1" data-align="left">DIT Can be Demonstrated by</th></tr></thead><tbody><tr><td class="align-left" data-colname="col1" data-align="left">1. A new T2 and/or gadolinium&#x2010;enhancing lesion(s) on follow&#x2010;up MRI, with reference to a baseline scan, irrespective of the timing of the baseline MRI</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">2. Simultaneous presence of asymptomatic gadolinium&#x2010;enhancing and nonenhancing lesions at any time</td></tr></tbody></table><ol class="noteGroup" id="brb3362-ntgp-0001" role="doc-endnotes"><li class="note" data-numbered="no" id="brb3362-note-0002" role="doc-footnote"><span class="generated-labeling"></span>

<p>MRI, magnetic resonance imaging; DIT, lesion dissemination in time.</p>
</li><li class="note" data-numbered="no" id="brb3362-note-0003" role="doc-footnote"><span class="generated-labeling"></span>

<p>Based on Montalban et&#xa0;al. <span class="link" data-href="#brb3362-bib-0500" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0500" aria-label="Montalban, 2010"><span class="generated-labeling">2010</span></a></span>.</p>
</li><li class="note" data-numbered="no" id="brb3362-note-0004" role="doc-footnote"><span class="generated-labeling"></span>

<p>Adapted from Polman et&#xa0;al. (<span class="link" data-href="#brb3362-bib-0084" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0084" aria-label="Polman, 2011"><span class="generated-labeling">2011</span></a></span>).</p>
</li></ol></figure><figure class="tabular" data-copyright="John Wiley &amp; Sons, Ltd" id="brb3362-tbl-0003"><figcaption>
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="tabular" data-generated_text="yes"><span class="object-name-title">Table </span><span class="generated-labeling">3</span></span><span class="title" data-type="main">McDonald MRI criteria for demonstration of DIS (Polman et&#xa0;al. <span class="link" data-href="#brb3362-bib-0084" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0084" aria-label="Polman, 2011"><span class="generated-labeling">2011</span></a></span>)</span></header></figcaption><table class="topbot pgwide" data-rowsep="0" data-colsep="0" data-pgwide="1" data-tgroup_cols="1"><colgroup><col data-colname="col1" data-colnum="1" data-colsep="0" /></colgroup><thead class="valign-top"><tr data-rowsep="1"><th class="eR align-left" data-colname="col1" data-align="left">DIS can be demonstrated by&#xa0;&#x2265;&#xa0;1 T2 lesions<span class="link" data-href="#brb3362-note-0008" data-note_label="yes"><a class="linkAnchor" href="#brb3362-note-0008"><span class="generated-labeling">a</span></a></span> in at least 2 of the 4 area of the CNS</th></tr></thead><tbody><tr><td class="align-left" data-colname="col1" data-align="left">Periventricular</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Juxtacortical</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Infratentorial</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Spinal cord<span class="link" data-href="#brb3362-note-0009" data-note_label="yes"><a class="linkAnchor" href="#brb3362-note-0009"><span class="generated-labeling">b</span></a></span></td></tr></tbody></table><ol class="noteGroup" id="brb3362-ntgp-0002" role="doc-endnotes"><li class="note" data-numbered="no" id="brb3362-note-0005" role="doc-footnote"><span class="generated-labeling"></span>

<p>MRI, magnetic resonance imaging; DIS, lesion dissemination in space; CNS, central nervous system.</p>
</li><li class="note" data-numbered="no" id="brb3362-note-0006" role="doc-footnote"><span class="generated-labeling"></span>

<p>Based on Swanton et&#xa0;al. <span class="link" data-href="#brb3362-bib-0501" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0501" aria-label="Swanton, 2006"><span class="generated-labeling">2006</span></a></span>, <span class="link" data-href="#brb3362-bib-0502" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0502" aria-label="Swanton, 2007"><span class="generated-labeling">2007</span></a></span>.</p>
</li><li class="note" data-numbered="no" id="brb3362-note-0007" role="doc-footnote"><span class="generated-labeling"></span>

<p>Adapted from Polman et&#xa0;al. (<span class="link" data-href="#brb3362-bib-0084" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0084" aria-label="Polman, 2011"><span class="generated-labeling">2011</span></a></span>).</p>
</li><li class="note" id="brb3362-note-0008" role="doc-footnote"><span class="generated-labeling">a</span>

<p>Gadolinium enhancement of lesions is not required for DIS.</p>
</li><li class="note" id="brb3362-note-0009" role="doc-footnote"><span class="generated-labeling">b</span>

<p>If a subject has a brainstem or spinal cord syndrome, the symptomatic lesions are excluded from the Criteria and do not contribute to lesion count.</p>
</li></ol></figure><p>In patients presenting with typical relapsing remitting symptoms and classic demyelination lesions (e.g., shown in Fig.&#xa0;<span class="link" data-href="#brb3362-fig-0002"><a class="linkAnchor" href="#brb3362-fig-0002"><span class="generated-labeling">2</span></a></span>) on neuroimaging meeting the radiological criteria, the differential diagnosis is limited and often no further diagnostic testing is indicated in these cases.</p><figure class="figure" id="brb3362-fig-0002"><div class="mediaResourceGroup">
<img class="mediaResource" src="image_n/brb3362-fig-0002.png" data-href="urn:x-wiley:21623279:media:brb3362:brb3362-fig-0002" alt="image" />



</div><figcaption class="caption-titled">
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="figure" data-generated_text="yes"><span class="object-name-title">Figure </span><span class="generated-labeling">2</span></span></header>Brain <span class="fc">MRI</span> axial fluid attenuated inversion recovery (<span class="fc">FLAIR</span>) image shows the characteristic periventricular areas of increased signal intensity (arrows) that are oriented perpendicular to and often contiguous with the lateral ventricles.</figcaption></figure><p>The differential diagnosis in other cases depends on the clinical presentation and is outlined in Table&#xa0;<span class="link" data-href="#brb3362-tbl-0004"><a class="linkAnchor" href="#brb3362-tbl-0004"><span class="generated-labeling">4</span></a></span>.</p><figure class="tabular" data-copyright="John Wiley &amp; Sons, Ltd" id="brb3362-tbl-0004"><figcaption>
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="tabular" data-generated_text="yes"><span class="object-name-title">Table </span><span class="generated-labeling">4</span></span><span class="title" data-type="main">Differential diagnosis of multiple sclerosis</span></header></figcaption><table class="topbot pgwide" data-rowsep="0" data-colsep="0" data-pgwide="1" data-tgroup_cols="1"><colgroup><col data-colname="col1" data-colnum="1" data-colsep="0" /></colgroup><tbody><tr><td class="align-left" data-colname="col1" data-align="left">Optic neuritis/neuropathy</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Inflammatory, neuromyelitis optica (NMO) spectrum disorder, genetic, ischemic</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Myelitis/myelopathy&#x2014;</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Inflammatory demyelination&#x2014;idiopathic, postviral, postvaccinialNMO spectrum disorder, Autoimmune&#x2013;systemic lupus erythematosus, antiphospholipid antibody syndrome, other systemic autoimmune disorders</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Infectious (Lyme disease, HIV, viral, others)</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Ischemic/vascular</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Others&#x2013;compressive, nutritional</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Brainstem syndrome</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Stroke, tumor, vasculitis (lupus, Sj&#xf6;gren's syndrome, Beh&#xe7;et's disease)</td></tr><tr><td class="align-left" data-colname="col1" data-align="left">Cerebral white matter lesions</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Small vessel disease (Leukoaraiosis)</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Migraine</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Primary CNS vasculitis</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Sarcoidosis</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)&#xa0;</td></tr></tbody></table></figure><section class="section" id="brb3362-sec-0009"><header class="titleGroup"><h3 class="title" data-type="main">Atypical presentation or variants of MS</h3></header><p>There are some less common clinical variants of MS which present with atypical clinical and radiological features, these include tumefactive MS, Balo's concentric sclerosis, and Marburg disease. The radiological hallmark of tumefactive MS is a large solitary &gt;2&#xa0;cm lesion associated with mass effect, edema and/or ring enhancement (hence the name tumefactive). The clinical symptoms depend on the size and location of the lesion and often include aphasia, agnosia, seizures and visual field defects, not typically seen in CIS or RRMS patients (Lucchinetti et&#xa0;al. <span class="link" data-href="#brb3362-bib-0067" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0067" aria-label="Lucchinetti, 2008"><span class="generated-labeling">2008</span></a></span>). Marburg's disease and Balo's concentric sclerosis are characterized by a rapidly evolving fulminant clinical course and poor prognosis. The Marburg variant has the distinct radiological feature of large tumor&#x2010;like multifocal demyelinating lesions in deep white matter; the pathological changes are similar to those of classicMS but may appear more destructive and have more inflammatory infiltrates (Karussis <span class="link" data-href="#brb3362-bib-0057" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0057" aria-label="Karussis, 2014"><span class="generated-labeling">2014</span></a></span>). The pathological changes seen in Balo's concentric sclerosis are quite unique and consist of alternating bands of normally myelinated or remyelinated, and demyelinated white matter; this pattern has been described as resembling hypoxia&#x2010;induced injury (Stadelmann et&#xa0;al. <span class="link" data-href="#brb3362-bib-0096" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0096" aria-label="Stadelmann, 2005"><span class="generated-labeling">2005</span></a></span>). The MRI may show alternating isointense and hypointense concentric rings with partial enhancement on T1&#x2010;weighted images (Zettl et&#xa0;al. <span class="link" data-href="#brb3362-bib-0112" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0112" aria-label="Zettl, 2012"><span class="generated-labeling">2012</span></a></span>; Karussis <span class="link" data-href="#brb3362-bib-0057" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0057" aria-label="Karussis, 2014"><span class="generated-labeling">2014</span></a></span>).</p></section></section><section class="section" id="brb3362-sec-0010" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Therapeutic Options</h2></header><p>The management of MS includes treatment with immunomodulatory agents that help alter the course of the disease, symptomatic management focusing on relieving specific symptoms such as fatigue, spasticity, bladder dysfunction, and pain (not discussed in this review). Corticosteroids (methylprednisolone) and adrenocorticotropic hormone (ACTH) have anti&#x2010;inflammatory and immunomodulatory effects and are typically used to treat acute relapse to hasten the recovery (Berkovich <span class="link" data-href="#brb3362-bib-0012" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0012" aria-label="Berkovich, 2013"><span class="generated-labeling">2013</span></a></span>). The immunomodulatory therapies (IMT) used in long&#x2010;term disease modification are discussed in the next section.</p></section><section class="section" id="brb3362-sec-0011" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Immunomodulatory Therapies</h2></header><p>The most significant progress in the treatment of MS in the last two decades has been the development of IMT. Since the introduction of first immunomodulating medication, interferon beta&#x2010;1b in 1993, several other medications with different mechanism of action (figure&#xa0;<span class="link" data-href="#brb3362-fig-0001"><a class="linkAnchor" href="#brb3362-fig-0001"><span class="generated-labeling">1</span></a></span>), mode and frequency of administration have become available. Currently, there are 12 medications approved for treatment of MS, including six self&#x2010;injectable, three infusion based, and three oral medications as listed in Table&#xa0;<span class="link" data-href="#brb3362-tbl-0005"><a class="linkAnchor" href="#brb3362-tbl-0005"><span class="generated-labeling">5</span></a></span>.</p><figure class="tabular" data-copyright="John Wiley &amp; Sons, Ltd" id="brb3362-tbl-0005"><figcaption>
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="tabular" data-generated_text="yes"><span class="object-name-title">Table </span><span class="generated-labeling">5</span></span><span class="title" data-type="main">Approved therapies for multiple sclerosis</span></header></figcaption><table class="topbot pgwide" data-rowsep="0" data-colsep="0" data-pgwide="1" data-tgroup_cols="5"><colgroup><col data-colname="col1" data-colnum="1" data-colsep="0" /><col data-colname="col2" data-colnum="2" data-colsep="0" /><col data-colname="col3" data-colnum="3" data-colsep="0" /><col data-colname="col4" data-colnum="4" data-colsep="0" /><col data-colname="col5" data-colnum="5" data-colsep="0" /></colgroup><thead class="valign-top"><tr data-rowsep="1"><th class="eR align-left" data-colname="col1" data-align="left">Medication</th><th class="eR align-left" data-colname="col2" data-align="left">Dose</th><th class="eR align-left" data-colname="col3" data-align="left">Route</th><th class="eR align-left" data-colname="col4" data-align="left">Frequency</th><th class="eR align-left" data-colname="col5" data-align="left">Major side effects</th></tr></thead><tbody><tr><td class="align-left" colspan="5" data-nameend="col5" data-namest="col1" data-align="left">First&#x2010;line therapies</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Beta&#x2010;interferon&#x2010;1b (Betaseron<sup>&#xae;</sup>, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ) </td><td class="align-left" data-colname="col2" data-align="left">250&#xa0;&#xb5;g</td><td class="align-left" data-colname="col3" data-align="left">SC</td><td class="align-left" data-colname="col4" data-align="left">Every other day</td><td class="align-left" rowspan="5" data-colname="col5" data-align="left">Flu&#x2010;like symptoms, injection site reactions, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and depression</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Beta&#x2010;interferon&#x2010;1a (Avonex<sup>&#xae;</sup>, Biogen Idec, Cambridge, MA )</td><td class="align-left" data-colname="col2" data-align="left">30&#xa0;&#xb5;g</td><td class="align-left" data-colname="col3" data-align="left">IM</td><td class="align-left" data-colname="col4" data-align="left">Once a week</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Peginterferon beta&#x2010;1a (Plegridy<sup>&#xae;</sup>, Biogen Idec, Cambridge, MA)</td><td class="align-left" data-colname="col2" data-align="left">125&#xa0;&#xb5;g</td><td class="align-left" data-colname="col3" data-align="left">SC</td><td class="align-left" data-colname="col4" data-align="left">Every 14&#xa0;days</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Beta&#x2010;interferon&#x2010;1a (Rebif<sup>&#xae;</sup>, EMD Serono, Inc. Rockland, MA )</td><td class="align-left" data-colname="col2" data-align="left">44&#xa0;&#xb5;g</td><td class="align-left" data-colname="col3" data-align="left">SC</td><td class="align-left" data-colname="col4" data-align="left">Three times weekly</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Beta&#x2010;interferon&#x2010;1b (Extavia<sup>&#xae;</sup>, Bayer HealthCare Pharmaceuticals Inc., Montville, NJ)</td><td class="align-left" data-colname="col2" data-align="left">250&#xa0;&#xb5;g</td><td class="align-left" data-colname="col3" data-align="left">SC</td><td class="align-left" data-colname="col4" data-align="left">Every other day</td></tr><tr><td class="indentLevel-1 align-left" rowspan="2" data-colname="col1" data-align="left" data-indent-level="1">Glatiramer acetate (Copaxone<sup>&#xae;</sup>, TEVA Neuroscience, Inc., Overland Park, KS )</td><td class="align-left" data-colname="col2" data-align="left">20&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">SC</td><td class="align-left" data-colname="col4" data-align="left">Daily</td><td class="align-left" rowspan="2" data-colname="col5" data-align="left">Local injection site reactions, postinjection reaction (flushing, chest tightness, palpitation, and dyspnea) and rare lipoatrophy with prolonged use</td></tr><tr><td class="align-left" data-colname="col2" data-align="left">40&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">SC</td><td class="align-left" data-colname="col4" data-align="left">Three times weekly</td></tr><tr><td class="align-left" colspan="5" data-nameend="col5" data-namest="col1" data-align="left">Second line therapies</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Natalizumab (Tysabri<sup>&#xae;</sup>, Biogen Idec, Cambridge, MA)</td><td class="align-left" data-colname="col2" data-align="left">300&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">IV</td><td class="align-left" data-colname="col4" data-align="left">Every 4&#xa0;weeks</td><td class="align-left" data-colname="col5" data-align="left">Hepatotoxicity, infusion reactions, progressive multifocal encephalopathy (PML)</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Mitoxantrone (Novantrone<sup>&#xae;</sup>, EMD Serono, Inc. Rockland, MA)</td><td class="align-left" data-colname="col2" data-align="left">Weight&#x2010;based dose</td><td class="align-left" data-colname="col3" data-align="left">IV</td><td class="align-left" data-colname="col4" data-align="left">Every 3&#xa0;months</td><td class="align-left" data-colname="col5" data-align="left">Cardiotoxicity, secondary leukemia</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Fingolimod (Gilenya<sup>&#xae;</sup>, Novartis Pharma Stein AG Stein, Switzerland)</td><td class="align-left" data-colname="col2" data-align="left">0.5&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">Oral</td><td class="align-left" data-colname="col4" data-align="left">Once daily</td><td class="align-left" data-colname="col5" data-align="left">First dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, rare risk of PML</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Teriflunomide (Aubagio<sup>&#xae;</sup>, Genzyme Corporation, Cambridge, MA)</td><td class="align-left" data-colname="col2" data-align="left">7 and 14&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">Oral</td><td class="align-left" data-colname="col4" data-align="left">Once daily</td><td class="align-left" data-colname="col5" data-align="left">Hair loss, headache, diarrhea, hepatotoxicity, teratogenicity, increased risk of infections due to lymphopenia</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Dimethyl fumarate (Tecfidera<sup>&#xae;</sup>, Biogen Idec., Cambridge, MA )</td><td class="align-left" data-colname="col2" data-align="left">240&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">Oral</td><td class="align-left" data-colname="col4" data-align="left">Twice daily</td><td class="align-left" data-colname="col5" data-align="left">GI effects&#x2010;nausea, diarrhea, abdominal pain, flushing, pruritus, liver enzyme elevation, lymphopenia, rare cases of PML</td></tr><tr><td class="indentLevel-1 align-left" data-colname="col1" data-align="left" data-indent-level="1">Alemtuzumab (Lemtrada<sup>&#xae;</sup>, Genzyme Corporation, Cambridge, MA )</td><td class="align-left" data-colname="col2" data-align="left">12&#xa0;mg or 24&#xa0;mg</td><td class="align-left" data-colname="col3" data-align="left">IV</td><td class="align-left" data-colname="col4" data-align="left">Per day (5&#xa0;days in year 1, 3&#xa0;days in year 2)</td><td class="align-left" data-colname="col5" data-align="left">Serious infusion reactions, secondary autoimmune diseases&#x2010;thryoiditis, thrombocytopenia, anti&#x2010;glomerual basement membrane disease, increased risk of malignancies&#x2014;thyroid cancer, melanoma, lymphoproliferative disorders</td></tr></tbody></table></figure><p>The mechanism of action of IMT used for treatment of MS is broad suppression of the immune response mediated by autoreactive lymphocytes; most of these are effective in relapsing remitting MS where inflammatory demyelination is the primary process (Weinstock&#x2010;Guttman et&#xa0;al. <span class="link" data-href="#brb3362-bib-0103" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0103" aria-label="Weinstock&#x2010;Guttman, 1995"><span class="generated-labeling">1995</span></a></span>; Rudick et&#xa0;al. <span class="link" data-href="#brb3362-bib-0088" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0088" aria-label="Rudick, 1997"><span class="generated-labeling">1997</span></a></span>; Damal et&#xa0;al. <span class="link" data-href="#brb3362-bib-0026" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0026" aria-label="Damal, 2013"><span class="generated-labeling">2013</span></a></span>). The goal of these therapies is to reduce the frequency of relapses and number of MRI lesions (new, enlarging and/or enhancing T2 lesions), and slow the disability progression. Most of these agents have shown good efficacy in patients with relapsing remitting MS and clinically isolated syndrome, however, their benefit in patients with progressive disease has been questionable (Filippini et&#xa0;al. <span class="link" data-href="#brb3362-bib-0032" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0032" aria-label="Filippini, 2013"><span class="generated-labeling">2013</span></a></span>). The mechanism of action and side&#x2010;effect profile of different IMTs are briefly discussed here with the exception of alemtuzumab, the latest medication to be approved for treatment of MS.</p></section><section class="section" id="brb3362-sec-0012" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Beta&#x2010;Interferon</h2></header><p>Interferons (IFNs) are endogenous proteins that are involved in immune response against viral and bacterial agents and were the first class of disease modifying agents developed for treatment of MS. The beta&#x2010;interferons (IFN&#x2010;<i>&#x3b2;</i>) have multiple actions including stabilizing the BBB thereby limiting the entry of T cells into the CNS, modulating T&#x2010; and B&#x2010;cell function, and altering the expression of cytokines (Yong et&#xa0;al. <span class="link" data-href="#brb3362-bib-0110" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0110" aria-label="Yong, 1998"><span class="generated-labeling">1998</span></a></span>; Weber et&#xa0;al. <span class="link" data-href="#brb3362-bib-0100" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0100" aria-label="Weber, 1999"><span class="generated-labeling">1999</span></a></span>; Dhib&#x2010;Jalbut <span class="link" data-href="#brb3362-bib-0027" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0027" aria-label="Dhib&#x2010;Jalbut, 2002"><span class="generated-labeling">2002</span></a></span>). Several different preparations of IFN&#x2010; <i>&#x3b2;</i> are available and are listed in Table&#xa0;<span class="link" data-href="#brb3362-tbl-0005"><a class="linkAnchor" href="#brb3362-tbl-0005"><span class="generated-labeling">5</span></a></span>. Both IFN&#x2010; <i>&#x3b2;</i>1a and IFN&#x2010;<i>&#x3b2;</i>1b have shown similar efficacy and are considered first line agents for treating patients with relapsing MS and CIS (Rudick et&#xa0;al. <span class="link" data-href="#brb3362-bib-0088" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0088" aria-label="Rudick, 1997"><span class="generated-labeling">1997</span></a></span>). Although two different trials with IFN&#x2010; <i>&#x3b2;</i>1b showed conflicting results in secondary progressive MS, it may be indicated in patients with continued relapses (Kappos et&#xa0;al. <span class="link" data-href="#brb3362-bib-0055" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0055" aria-label="Kappos, 2004"><span class="generated-labeling">2004</span></a></span>). The side effects of beta&#x2010;interferon include flu&#x2010;like symptoms, depression, liver enzyme elevation, thyroid abnormalities, leukopenia or anemia, and injection site reactions (Rudick et&#xa0;al. <span class="link" data-href="#brb3362-bib-0088" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0088" aria-label="Rudick, 1997"><span class="generated-labeling">1997</span></a></span>).</p></section><section class="section" id="brb3362-sec-0013" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Glatiramer Acetate</h2></header><p>Glatiramer acetate (GA) or Copolymer 1 is a synthetic complex of four amino acids that mimics myelin basic protein (MBP), one of the autoantigens targeted by the T cells. Due to its structural similarity to MBP, GA blocks the formation of myelin reactive T cells and induces GA&#x2010;specific regulatory T&#x2010;cell expression and Th2 anti&#x2010;inflammatory cytokine production (bystander suppression) (Wolinsky <span class="link" data-href="#brb3362-bib-0106" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0106" aria-label="Wolinsky, 1995"><span class="generated-labeling">1995</span></a></span>; Rudick et&#xa0;al. <span class="link" data-href="#brb3362-bib-0088" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0088" aria-label="Rudick, 1997"><span class="generated-labeling">1997</span></a></span>; Gran et&#xa0;al. <span class="link" data-href="#brb3362-bib-0045" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0045" aria-label="Gran, 2000"><span class="generated-labeling">2000</span></a></span>; Dhib&#x2010;Jalbut <span class="link" data-href="#brb3362-bib-0027" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0027" aria-label="Dhib&#x2010;Jalbut, 2002"><span class="generated-labeling">2002</span></a></span>; Ruggieri et&#xa0;al. <span class="link" data-href="#brb3362-bib-0089" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0089" aria-label="Ruggieri, 2007"><span class="generated-labeling">2007</span></a></span>). The clinical efficacy of GA in terms of reducing relapse rate and MRI lesions is similar to IFN&#x2010;<i>&#x3b2;</i>, however, GA has somewhat limited effect on disability progression (Rudick et&#xa0;al. <span class="link" data-href="#brb3362-bib-0088" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0088" aria-label="Rudick, 1997"><span class="generated-labeling">1997</span></a></span>; La Mantia et&#xa0;al. <span class="link" data-href="#brb3362-bib-0060" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0060" aria-label="La Mantia, 2010"><span class="generated-labeling">2010</span></a></span>). The side effect profile of GA is, however, more favorable and includes local injection site reactions, post injection reaction (flushing, chest tightness, palpitation, and dyspnea within minutes of injection with spontaneous resolution) and rare lipoatrophy with prolonged use.</p></section><section class="section" id="brb3362-sec-0014" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Natalizumab</h2></header><p>Natalizumab is a humanized monoclonal antibody that binds <i>&#x3b1;</i>4<i>&#x3b2;</i>1&#x2010;integrin on lymphocytes blocking their interaction with VCAM&#x2010;1 on endothelial cells thereby preventing the transmigration of lymphocytes across the BBB (Ransohoff <span class="link" data-href="#brb3362-bib-0087" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0087" aria-label="Ransohoff, 2007"><span class="generated-labeling">2007</span></a></span>). Its superior efficacy has been demonstrated in two phase 3 studies with a robust effect on relapse rate reduction and disability progression (Miller et&#xa0;al. <span class="link" data-href="#brb3362-bib-0072" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0072" aria-label="Miller, 2003"><span class="generated-labeling">2003</span></a></span>; Polman et&#xa0;al. <span class="link" data-href="#brb3362-bib-0083" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0083" aria-label="Polman, 2006"><span class="generated-labeling">2006</span></a></span>). The major safety concern with natalizumab is progressive multifocal leukoencephalopathy (PML), a serious potentially fatal opportunistic brain infection caused by reactivation of JC virus (Yousry et&#xa0;al. <span class="link" data-href="#brb3362-bib-0111" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0111" aria-label="Yousry, 2006"><span class="generated-labeling">2006</span></a></span>). As of December 2014, 514 cases of PML have been reported worldwide with postmarketing use of natalizumab (TYSABRI [natalizumab] <span class="link" data-href="#brb3362-bib-1002" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-1002" aria-label="TYSABRI&#xae; (natalizumab): PML Incidence in Patients Receiving TYSABRI, 2014"><span class="generated-labeling">2014</span></a></span>). The overall risk of PML in MS patients with natalizumab use is 3.78 per 1000 with a much higher risk (13/1000) among patients with prolonged duration of therapy (&#x2265;24&#xa0;months), history of prior immunosuppressive therapy, and positive JC virus antibody status (Bloomgren et&#xa0;al. <span class="link" data-href="#brb3362-bib-0013" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0013" aria-label="Bloomgren, 2012"><span class="generated-labeling">2012</span></a></span>; Information M, <span class="link" data-href="#brb3362-bib-1002" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-1002" aria-label="TYSABRI&#xae; (natalizumab): PML Incidence in Patients Receiving TYSABRI, 2014"><span class="generated-labeling">2014</span></a></span>). Due to the risk of PML, natalizumab now has a more limited use as a second line drug in patients with breakthrough disease or intolerable side effects with first line therapies.</p></section><section class="section" id="brb3362-sec-0015" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Mitoxantrone</h2></header><p>Mitoxantrone is a synthetic anthracendione antineoplastic agent; its immunomodulatory effects include suppression of T and B lymphocytes and macrophage proliferation. Mitoxantrone is indicated for reducing disability and relapse frequency in patients with worsening relapsing remitting and secondary&#x2010;progressive MS, however, its use has been limited due to risk of dose&#x2010;related cardiotoxicity and treatment&#x2010;related leukemia (Fox <span class="link" data-href="#brb3362-bib-0033" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0033" aria-label="Fox, 2006"><span class="generated-labeling">2006</span></a></span>).</p></section><section class="section" id="brb3362-sec-0016" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Oral Therapies</h2></header><p>Three new oral medications have recently become available for treatment of relapsing MS: fingolimod, teriflunomide, and dimethylfumarate. The efficacy of these medications has been established in several phase 3 studies with comparable or somewhat better effect (compared to some injectable therapies) on relapse rate reduction, MRI lesions, and disability progression.</p><p><i>Fingolimod</i> is a sphingosine&#x2010;1&#x2010;phosphate receptor (S1P1) modulator and was the first oral drug approved for treatment of MS. By binding to S1P1 receptor on the T cells, it prevents emigration of activated T cells from lymph nodes thereby limiting their entry into the CNS (Chiba et&#xa0;al. <span class="link" data-href="#brb3362-bib-0019" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0019" aria-label="Chiba, 1998"><span class="generated-labeling">1998</span></a></span>; Pelletier and Hafler <span class="link" data-href="#brb3362-bib-0082" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0082" aria-label="Pelletier, 2012"><span class="generated-labeling">2012</span></a></span>). The potential side effects of fingolimod include first dose bradycardia, atrioventricular block, herpes virus infection, macular edema, elevated blood pressure, and a reported cases of PML (Cohen et&#xa0;al. <span class="link" data-href="#brb3362-bib-0021" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0021" aria-label="Cohen, 2010"><span class="generated-labeling">2010</span></a></span>; Kappos et&#xa0;al. <span class="link" data-href="#brb3362-bib-0056" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0056" aria-label="Kappos, 2010"><span class="generated-labeling">2010</span></a></span>; Samson <span class="link" data-href="#brb3362-bib-0090" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0090" aria-label="Samson, 2013"><span class="generated-labeling">2013</span></a></span>; Calic et&#xa0;al. <span class="link" data-href="#brb3362-bib-0017" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0017" aria-label="Calic, 2015"><span class="generated-labeling">2015</span></a></span>).</p><p>There have been a total of three reported cases of PML associated with use of fingolimod, two of these occurred in context of prior immunosuppressive therapy, the third most recent case, however, was reported in a patient with no prior immunosuppressive therapy after more than 4&#xa0;years of fingolimod use (Calic et&#xa0;al. <span class="link" data-href="#brb3362-bib-0017" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0017" aria-label="Calic, 2015"><span class="generated-labeling">2015</span></a></span>; Case of PML reported in patient treated with Gilenya, <span class="link" data-href="#brb3362-bib-0018" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0018" aria-label="Case of PML reported in patient treated with Gilenya, 2015"><span class="generated-labeling">2015</span></a></span>). A single case of sudden suspected cardiac death within 24&#xa0;h of taking first dose of fingolimod was reported in December 2011 (Lindsey et&#xa0;al. <span class="link" data-href="#brb3362-bib-0061" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0061" aria-label="Lindsey, 2012"><span class="generated-labeling">2012</span></a></span>). Even though a direct association with the medication could not be established, the US Food and Drug Administration and European regulatory agency released new monitoring guidelines for first dose monitoring and the drug is now contraindicated in patients with history of cardiac disease or stroke and patients on antiarrhythmic medications.</p><p><i>Teriflunomide</i> is an active metabolite of leflunomide (a drug used to treat rheumatoid arthritis) and is an inhibitor of enzyme dihyrdro&#x2010;orotate dehydrogenase (DHODH) which interferes with denovo synthesis of pyrimidine in rapidly dividing cells (Oh and O'Connor <span class="link" data-href="#brb3362-bib-0079" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0079" aria-label="Oh, 2013"><span class="generated-labeling">2013</span></a></span>). Its anti&#x2010;inflammatory effect in MS is believed to be mediated by reducing the activity of proliferating T and B lymphocytes. Teriflunomide does not affect the resting or slowly dividing hematopoietic cells which use the alternate DHODH independent &#x201c;salvage pathway&#x201d; for pyrimidine synthesis, therefore, preserving the basic homeostatic functions of these cells and immune surveillance (Oh and O'Connor <span class="link" data-href="#brb3362-bib-0079" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0079" aria-label="Oh, 2013"><span class="generated-labeling">2013</span></a></span>). Leflunomide is converted almost entirely into teriflunomide after absorption and taken at the recommended doses, both drugs result in similar plasma concentration of teriflunomide (AUBAGIO<sup>&#xae;</sup> (teriflunomide) Prescibing information. <span class="link" data-href="#brb3362-bib-1102" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-1102" aria-label="AUBAGIO&#xae; (teriflunomide) Prescibing information, 2014"><span class="generated-labeling">2014</span></a></span>). The short&#x2010;term side effects of teriflunomide are relatively mild and include hair loss, headache, diarrhea, and elevated liver enzymes (O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0078" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0078" aria-label="O'Connor, 2011"><span class="generated-labeling">2011</span></a></span>). Reduction in lymphocyte and neutrophil counts, elevated blood pressure, and a single case of latent tuberculosis are some of the other side effects reported (O'Connor et&#xa0;al. <span class="link" data-href="#brb3362-bib-0078" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0078" aria-label="O'Connor, 2011"><span class="generated-labeling">2011</span></a></span>; Confavreux et&#xa0;al. <span class="link" data-href="#brb3362-bib-0023" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0023" aria-label="Confavreux, 2014"><span class="generated-labeling">2014</span></a></span>). The potential teratogenecity of teriflunomide remains a major concern although several pregnancies reported during its clinical trial did not have any adverse outcome. Nevertheless, strict contraception is recommended to avoid pregnancy and a rapid elimination process is undertaken in women who become pregnant while taking teriflunomide as the drug can remain in the systems for 8&#xa0;months to 2&#xa0;years (Confavreux et&#xa0;al. <span class="link" data-href="#brb3362-bib-0023" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0023" aria-label="Confavreux, 2014"><span class="generated-labeling">2014</span></a></span>).</p><p><i>Dimethylfumarate (DMF) or BG12</i> is the latest oral therapy to be approved for treatment of MS. Related to fumaric acid ester which has been used for treatment of psoriasis in Germany since 1990s; BG12 is as an enteric coated formulation of DMF with improved GI tolerability. It is hydrolyzed to monomethyl fumarate soon after oral absorption. The mechanism of action of DMF involves inhibition of proinflammatory pathways via activation of nuclear factor erythroid 2&#x2010;related factor 2 (Nrf&#x2010;2) antioxidant response pathway (Linker et&#xa0;al. <span class="link" data-href="#brb3362-bib-0063" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0063" aria-label="Linker, 2011"><span class="generated-labeling">2011</span></a></span>). The most common side effect with DMF include nausea, diarrhea, abdominal pain which can be minimized by taking the medication with food and flushing which can be reduced by aspirin (Gold et&#xa0;al. <span class="link" data-href="#brb3362-bib-0043" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0043" aria-label="Gold, 2012"><span class="generated-labeling">2012</span></a></span>; Fox et&#xa0;al. <span class="link" data-href="#brb3362-bib-0035" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0035" aria-label="Fox, 2014"><span class="generated-labeling">2014</span></a></span>). Lymphopenia may occur although no increased infection risk was observed in phase 3 studies (Fox et&#xa0;al. <span class="link" data-href="#brb3362-bib-0034" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0034" aria-label="Fox, 2012"><span class="generated-labeling">2012</span></a></span>; Gold et&#xa0;al. <span class="link" data-href="#brb3362-bib-0043" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0043" aria-label="Gold, 2012"><span class="generated-labeling">2012</span></a></span>). There have been a few cases of PML reported with use of fumaric acid ester formulations in patients with psoriasis with pronounced prolonged lymphopenia being the major risk factor (Ermis et&#xa0;al. <span class="link" data-href="#brb3362-bib-0028" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0028" aria-label="Ermis, 2013"><span class="generated-labeling">2013</span></a></span>; van Oosten et&#xa0;al. <span class="link" data-href="#brb3362-bib-0080" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0080" aria-label="Oosten, 2013"><span class="generated-labeling">2013</span></a></span>; Sweetser et&#xa0;al. <span class="link" data-href="#brb3362-bib-0097" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0097" aria-label="Sweetser, 2013"><span class="generated-labeling">2013</span></a></span>). There has been a recent report of a fatal case of PML in a patient with multiple sclerosis treated with dimethyl fumarate (FDA Drug Safety Communication, <span class="link" data-href="#brb3362-bib-0030" data-bib_callout_style="nameDate"><a class="linkAnchor" href="#brb3362-bib-0030" aria-label="FDA Drug Safety Communication, 2014"><span class="generated-labeling">2014</span></a></span>). In response to these cases of PML, JC virus antibody testing and close monitoring for lymphopenia has been suggested in patients initiating DMF therapy to improve surveillance.</p><p>The oral medications are currently considered second line due to a greater risk of serious side effects making their safety profile less favorable in patients with early and mild disease. The main safety concern with oral medications is the potential for prolonged immunosuppression increasing the risk of serious infections and also malignancies due to altered immune surveillance. A simplified treatment algorithm for patients with RRMS and CIS is outlined in Figure&#xa0;<span class="link" data-href="#brb3362-fig-0003"><a class="linkAnchor" href="#brb3362-fig-0003"><span class="generated-labeling">3</span></a></span>.</p><figure class="figure" id="brb3362-fig-0003"><div class="mediaResourceGroup">
<img class="mediaResource" src="image_n/brb3362-fig-0003.png" data-href="urn:x-wiley:21623279:media:brb3362:brb3362-fig-0003" alt="image" />



</div><figcaption class="caption-titled">
<header class="titleGroup"><span class="title" data-type="objectName" data-element_class="figure" data-generated_text="yes"><span class="object-name-title">Figure </span><span class="generated-labeling">3</span></span></header>Treatment approach to patients with <span class="fc">RRMS</span> and <span class="fc">CIS</span>.</figcaption></figure><p>In summary, there has been significant progress in the field of MS with better understanding of immunopathogenesis, wider availability and use of MRI, and availability of disease modifying therapies. There are currently a wide range of therapeutic options to treat MS including the recently approved oral drugs. However, balancing the safety and efficacy of these drugs remains a challenge due to serious side effects associated with more effective therapies. Given the heterogeneity of MS, personalized treatment by recognizing specific genetic markers in individual patients has been proposed. Also, there is an urgent need for novel therapeutic agents that can prevent or minimize the neuronal and/or axonal degeneration occurring in patients with progressive MS.</p></section><section class="section" id="brb3362-sec-0017" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">Conflict of Interest</h2></header><p>None declared.</p></section><section class="bibliography" data-cited="yes" data-style="nameDate" id="brb3362-bibl-0001" lang="en"><header class="titleGroup"><h2 class="title" data-type="main">References</h2></header><ul class="biblioentrylist"><li class="bib" id="brb3362-bib-0002"><span class="citation" data-type="journal" id="brb3362-cit-0002" role="doc-biblioentry"><span class="author"><span class="familyName">Aichele</span>, <span class="givenNames">P.</span></span>, <span class="author"><span class="givenNames">M. F.</span> <span class="familyName">Bachmann</span></span>, <span class="author"><span class="givenNames">H.</span> <span class="familyName">Hengartner</span></span>, and <span class="author"><span class="givenNames">R. M.</span> <span class="familyName">Zinkernagel</span></span>. <span class="pubYear" data-year="1996">1996</span>. <span class="articleTitle">Immunopathology or organ&#x2010;specific autoimmunity as a consequence of virus infection</span>. <span class="journalTitle">Immunol. Rev.</span> <span class="vol">152</span>:<span class="pageFirst">21</span>&#x2013;<span class="pageLast">45</span>.</span></li><li class="bib" id="brb3362-bib-0003"><span class="citation" data-type="journal" id="brb3362-cit-0003" role="doc-biblioentry"><span class="author"><span class="familyName">Ascherio</span>, <span class="givenNames">A.</span></span> <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Environmental factors in multiple sclerosis</span>. <span class="journalTitle">Expert Rev. Neurother.</span> <span class="vol">13</span>:<span class="pageFirst">3</span>&#x2013;<span class="pageLast">9</span>.</span></li><li class="bib" id="brb3362-bib-0004"><span class="citation" data-type="journal" id="brb3362-cit-0004" role="doc-biblioentry"><span class="author"><span class="familyName">Ascherio</span>, <span class="givenNames">A.</span></span>, and <span class="author"><span class="givenNames">K. L.</span> <span class="familyName">Munger</span></span>. <span class="pubYear" data-year="2007">2007a</span>. <span class="articleTitle">Environmental risk factors for multiple sclerosis. Part I: the role of infection</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">61</span>:<span class="pageFirst">288</span>&#x2013;<span class="pageLast">299</span>.</span></li><li class="bib" id="brb3362-bib-0005"><span class="citation" data-type="journal" id="brb3362-cit-0005" role="doc-biblioentry"><span class="author"><span class="familyName">Ascherio</span>, <span class="givenNames">A.</span></span>, and <span class="author"><span class="givenNames">K. L.</span> <span class="familyName">Munger</span></span>. <span class="pubYear" data-year="2007">2007b</span>. <span class="articleTitle">Environmental risk factors for multiple sclerosis. Part II: noninfectious factors</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">61</span>:<span class="pageFirst">504</span>&#x2013;<span class="pageLast">513</span>.</span></li><li class="bib" id="brb3362-bib-0006"><span class="citation" data-type="journal" id="brb3362-cit-0006" role="doc-biblioentry"><span class="author"><span class="familyName">Ascherio</span>, <span class="givenNames">A.</span></span>, <span class="author"><span class="givenNames">K. L.</span> <span class="familyName">Munger</span></span>, and <span class="author"><span class="givenNames">K. C.</span> <span class="familyName">Simon</span></span>. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">Vitamin D and multiple sclerosis</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">9</span>:<span class="pageFirst">599</span>&#x2013;<span class="pageLast">612</span>.</span></li><li class="bib" id="brb3362-bib-1102"><span class="citation" data-type="other" id="brb3362-cit-1102" role="doc-biblioentry"><span class="groupName">AUBAGIO<sup>&#xae;</sup> (teriflunomide) Prescibing information</span>. <span class="pubYear" data-year="2014">2014</span>. Genzyme Corp. (Accessed July 23, 2014).</span></li><li class="bib" id="brb3362-bib-0007"><span class="citation" data-type="journal" id="brb3362-cit-0007" role="doc-biblioentry"><span class="author"><span class="familyName">Awad</span>, <span class="givenNames">A.</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Hemmer</span></span>, <span class="author"><span class="givenNames">H. P.</span> <span class="familyName">Hartung</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Kieseier</span></span>, <span class="author"><span class="givenNames">J. L.</span> <span class="familyName">Bennett</span></span>, and <span class="author"><span class="givenNames">O.</span> <span class="familyName">Stuve</span></span>. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis</span>. <span class="journalTitle">J. Neuroimmunol.</span> <span class="vol">219</span>:<span class="pageFirst">1</span>&#x2013;<span class="pageLast">7</span>.</span></li><li class="bib" id="brb3362-bib-0008"><span class="citation" data-type="journal" id="brb3362-cit-0008" role="doc-biblioentry"><span class="author"><span class="familyName">Barcellos</span>, <span class="givenNames">L. F.</span></span>, <span class="author"><span class="givenNames">J. R.</span> <span class="familyName">Oksenberg</span></span>, <span class="author"><span class="givenNames">A. B.</span> <span class="familyName">Begovich</span></span>, <span class="author"><span class="givenNames">E. R.</span> <span class="familyName">Martin</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Schmidt</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Vittinghoff</span></span>, et&#xa0;al. <span class="pubYear" data-year="2003">2003</span>. <span class="articleTitle">HLA&#x2010;DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course</span>. <span class="journalTitle">Am. J. Hum. Genet.</span> <span class="vol">72</span>:<span class="pageFirst">710</span>&#x2013;<span class="pageLast">716</span>.</span></li><li class="bib" id="brb3362-bib-0009"><span class="citation" data-type="journal" id="brb3362-cit-0009" role="doc-biblioentry"><span class="author"><span class="familyName">Barkhof</span>, <span class="givenNames">F.</span></span>, <span class="author"><span class="givenNames">W.</span> <span class="familyName">Bruck</span></span>, <span class="author"><span class="givenNames">C. J.</span> <span class="familyName">De Groot</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Bergers</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Hulshof</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Geurts</span></span>, et&#xa0;al. <span class="pubYear" data-year="2003">2003</span>. <span class="articleTitle">Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance</span>. <span class="journalTitle">Arch. Neurol.</span> <span class="vol">60</span>:<span class="pageFirst">1073</span>&#x2013;<span class="pageLast">1081</span>.</span></li><li class="bib" id="brb3362-bib-0010"><span class="citation" data-type="journal" id="brb3362-cit-0010" role="doc-biblioentry"><span class="author"><span class="familyName">Barnett</span>, <span class="givenNames">M. H.</span></span>, and <span class="author"><span class="givenNames">J. W.</span> <span class="familyName">Prineas</span></span>. <span class="pubYear" data-year="2004">2004</span>. <span class="articleTitle">Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">55</span>:<span class="pageFirst">458</span>&#x2013;<span class="pageLast">468</span>.</span></li><li class="bib" id="brb3362-bib-0011"><span class="citation" data-type="journal" id="brb3362-cit-0011" role="doc-biblioentry"><span class="author"><span class="familyName">Batoulis</span>, <span class="givenNames">H.</span></span>, <span class="author"><span class="givenNames">K.</span> <span class="familyName">Addicks</span></span>, and <span class="author"><span class="givenNames">S.</span> <span class="familyName">Kuerten</span></span>. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm</span>. <span class="journalTitle">Annals Anat.</span> <span class="vol">192</span>:<span class="pageFirst">179</span>&#x2013;<span class="pageLast">193</span>.</span></li><li class="bib" id="brb3362-bib-0012"><span class="citation" data-type="journal" id="brb3362-cit-0012" role="doc-biblioentry"><span class="author"><span class="familyName">Berkovich</span>, <span class="givenNames">R.</span></span> <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Treatment of acute relapses in multiple sclerosis</span>. <span class="journalTitle">Neurotherapeutics</span> <span class="vol">10</span>:<span class="pageFirst">97</span>&#x2013;<span class="pageLast">105</span>.</span></li><li class="bib" id="brb3362-bib-0013"><span class="citation" data-type="journal" id="brb3362-cit-0013" role="doc-biblioentry"><span class="author"><span class="familyName">Bloomgren</span>, <span class="givenNames">G.</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Richman</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Hotermans</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Subramanyam</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Goelz</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Natarajan</span></span>, et&#xa0;al. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Risk of natalizumab&#x2010;associated progressive multifocal leukoencephalopathy</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">366</span>:<span class="pageFirst">1870</span>&#x2013;<span class="pageLast">1880</span>.</span></li><li class="bib" id="brb3362-bib-0014"><span class="citation" data-type="journal" id="brb3362-cit-0014" role="doc-biblioentry"><span class="author"><span class="familyName">Bogdan</span>, <span class="givenNames">F. P.</span></span>, <span class="author"><span class="givenNames">I.</span> <span class="familyName">Pirko</span></span>, <span class="author"><span class="givenNames">F. C.</span> <span class="familyName">Lucchinetti</span></span>, <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Pathology of multiple sclerosis: Where do we stand?</span>. <span class="journalTitle">Cont. Lifelong Learn. Neurol.</span> <span class="vol">19</span>:<span class="pageFirst">901</span>&#x2013;<span class="pageLast">921</span>.</span></li><li class="bib" id="brb3362-bib-0015"><span class="citation" data-type="journal" id="brb3362-cit-0015" role="doc-biblioentry"><span class="author"><span class="familyName">Bruck</span>, <span class="givenNames">W.</span></span>, and <span class="author"><span class="givenNames">C.</span> <span class="familyName">Stadelmann</span></span>. <span class="pubYear" data-year="2005">2005</span>. <span class="articleTitle">The spectrum of multiple sclerosis: new lessons from pathology</span>. <span class="journalTitle">Curr. Opin. Neurol.</span> <span class="vol">18</span>:<span class="pageFirst">221</span>&#x2013;<span class="pageLast">224</span>.</span></li><li class="bib" id="brb3362-bib-0016"><span class="citation" data-type="journal" id="brb3362-cit-0016" role="doc-biblioentry"><span class="author"><span class="familyName">Bruck</span>, <span class="givenNames">W.</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Porada</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Poser</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Rieckmann</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Hanefeld</span></span>, <span class="author"><span class="givenNames">H. A.</span> <span class="familyName">Kretzschmar</span></span>, et&#xa0;al. <span class="pubYear" data-year="1995">1995</span>. <span class="articleTitle">Monocyte/macrophage differentiation in early multiple sclerosis lesions</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">38</span>:<span class="pageFirst">788</span>&#x2013;<span class="pageLast">796</span>.</span></li><li class="bib" id="brb3362-bib-0017"><span class="citation" data-type="journal" id="brb3362-cit-0017" role="doc-biblioentry"><span class="author"><span class="familyName">Calic</span>, <span class="givenNames">Z.</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Cappelen&#x2010;Smith</span></span>, <span class="author"><span class="givenNames">S. J.</span> <span class="familyName">Hodgkinson</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">McDougall</span></span>, <span class="author"><span class="givenNames">R.</span> <span class="familyName">Cuganesan</span></span>, and <span class="author"><span class="givenNames">B. J.</span> <span class="familyName">Brew</span></span>. <span class="pubYear" data-year="2015">2015</span>. <span class="articleTitle">Treatment of progressive multifocal leukoencephalopathy&#x2010;immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab</span>. <span class="journalTitle">J. Clin. Neurosci.</span> <span class="vol">22</span>:<span class="pageFirst">598</span>&#x2013;<span class="pageLast">600</span>.</span></li><li class="bib" id="brb3362-bib-0018"><span class="citation" data-type="other" id="brb3362-cit-0018" role="doc-biblioentry"><span class="groupName">Case of PML reported in patient treated with Gilenya</span>&#xae;. <span class="url"><a class="urlAnchor" href="https://beta.mssociety.ca/research-news/article/case-of-pml-reported-in-patient-treated-with-gilenya" target="_blank">https://beta.mssociety.ca/research-news/article/case-of-pml-reported-in-patient-treated-with-gilenya</a></span>, <span class="pubYear" data-year="2015">2015</span>.</span></li><li class="bib" id="brb3362-bib-0019"><span class="citation" data-type="journal" id="brb3362-cit-0019" role="doc-biblioentry"><span class="author"><span class="familyName">Chiba</span>, <span class="givenNames">K.</span></span>, <span class="author"><span class="givenNames">Y.</span> <span class="familyName">Yanagawa</span></span>, <span class="author"><span class="givenNames">Y.</span> <span class="familyName">Masubuchi</span></span>, <span class="author"><span class="givenNames">H.</span> <span class="familyName">Kataoka</span></span>, <span class="author"><span class="givenNames">T.</span> <span class="familyName">Kawaguchi</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Ohtsuki</span></span>, et&#xa0;al. <span class="pubYear" data-year="1998">1998</span>. <span class="articleTitle">FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing</span>. <span class="journalTitle">J. Immunol.</span> <span class="vol">160</span>:<span class="pageFirst">5037</span>&#x2013;<span class="pageLast">5044</span>.</span></li><li class="bib" id="brb3362-bib-0020"><span class="citation" data-type="journal" id="brb3362-cit-0020" role="doc-biblioentry"><span class="author"><span class="familyName">Cifelli</span>, <span class="givenNames">A.</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Arridge</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Jezzard</span></span>, <span class="author"><span class="givenNames">M. M.</span> <span class="familyName">Esiri</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Palace</span></span>, and <span class="author"><span class="givenNames">P. M.</span> <span class="familyName">Matthews</span></span>. <span class="pubYear" data-year="2002">2002</span>. <span class="articleTitle">Thalamic neurodegeneration in multiple sclerosis</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">52</span>:<span class="pageFirst">650</span>&#x2013;<span class="pageLast">653</span>.</span></li><li class="bib" id="brb3362-bib-0021"><span class="citation" data-type="journal" id="brb3362-cit-0021" role="doc-biblioentry"><span class="author"><span class="familyName">Cohen</span>, <span class="givenNames">J. A.</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Barkhof</span></span>, <span class="author"><span class="givenNames">G.</span> <span class="familyName">Comi</span></span>, <span class="author"><span class="givenNames">H. P.</span> <span class="familyName">Hartung</span></span>, <span class="author"><span class="givenNames">B. O.</span> <span class="familyName">Khatri</span></span>, <span class="author"><span class="givenNames">X.</span> <span class="familyName">Montalban</span></span>, et&#xa0;al. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">362</span>:<span class="pageFirst">402</span>&#x2013;<span class="pageLast">415</span>.</span></li><li class="bib" id="brb3362-bib-0022"><span class="citation" data-type="journal" id="brb3362-cit-0022" role="doc-biblioentry"><span class="author"><span class="familyName">Compston</span>, <span class="givenNames">A.</span></span>, and <span class="author"><span class="givenNames">A.</span> <span class="familyName">Coles</span></span>. <span class="pubYear" data-year="2008">2008</span>. <span class="articleTitle">Multiple sclerosis</span>. <span class="journalTitle">Lancet</span> <span class="vol">372</span>:<span class="pageFirst">1502</span>&#x2013;<span class="pageLast">1517</span>.</span></li><li class="bib" id="brb3362-bib-0023"><span class="citation" data-type="journal" id="brb3362-cit-0023" role="doc-biblioentry"><span class="author"><span class="familyName">Confavreux</span>, <span class="givenNames">C.</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">O'Connor</span></span>, <span class="author"><span class="givenNames">G.</span> <span class="familyName">Comi</span></span>, <span class="author"><span class="givenNames">M. S.</span> <span class="familyName">Freedman</span></span>, <span class="author"><span class="givenNames">A. E.</span> <span class="familyName">Miller</span></span>, <span class="author"><span class="givenNames">T. P.</span> <span class="familyName">Olsson</span></span>, et&#xa0;al. <span class="pubYear" data-year="2014">2014</span>. <span class="articleTitle">Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 3 trial</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">13</span>:<span class="pageFirst">247</span>&#x2013;<span class="pageLast">256</span>.</span></li><li class="bib" id="brb3362-bib-0024"><span class="citation" data-type="journal" id="brb3362-cit-0024" role="doc-biblioentry"><span class="author"><span class="familyName">Conradi</span>, <span class="givenNames">S.</span></span>, <span class="author"><span class="givenNames">U.</span> <span class="familyName">Malzahn</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Schroter</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Paul</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Quill</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Spruth</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Environmental factors in early childhood are associated with multiple sclerosis: a case&#x2010;control study</span>. <span class="journalTitle">BMC Neurol.</span> <span class="vol">11</span>:<span class="pageFirst">123</span>.</span></li><li class="bib" id="brb3362-bib-0025"><span class="citation" data-type="journal" id="brb3362-cit-0025" role="doc-biblioentry"><span class="author"><span class="familyName">Correale</span>, <span class="givenNames">J.</span></span>, <span class="author"><span class="givenNames">M. C.</span> <span class="familyName">Ysrraelit</span></span>, and <span class="author"><span class="givenNames">M. I.</span> <span class="familyName">Gaitan</span></span>. <span class="pubYear" data-year="2009">2009</span>. <span class="articleTitle">Immunomodulatory effects of Vitamin D in multiple sclerosis</span>. <span class="journalTitle">Brain</span> <span class="vol">132</span>:<span class="pageFirst">1146</span>&#x2013;<span class="pageLast">1160</span>.</span></li><li class="bib" id="brb3362-bib-0026"><span class="citation" data-type="journal" id="brb3362-cit-0026" role="doc-biblioentry"><span class="author"><span class="familyName">Damal</span>, <span class="givenNames">K.</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Stoker</span></span>, and <span class="author"><span class="givenNames">J. F.</span> <span class="familyName">Foley</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action</span>. <span class="journalTitle">Biologics</span> <span class="vol">7</span>:<span class="pageFirst">247</span>&#x2013;<span class="pageLast">258</span>.</span></li><li class="bib" id="brb3362-bib-0027"><span class="citation" data-type="journal" id="brb3362-cit-0027" role="doc-biblioentry"><span class="author"><span class="familyName">Dhib&#x2010;Jalbut</span>, <span class="givenNames">S.</span></span> <span class="pubYear" data-year="2002">2002</span>. <span class="articleTitle">Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis</span>. <span class="journalTitle">Neurology</span> <span class="vol">58</span>:<span class="pageFirst">S3</span>&#x2013;<span class="pageLast">S9</span>.</span></li><li class="bib" id="brb3362-bib-0028"><span class="citation" data-type="journal" id="brb3362-cit-0028" role="doc-biblioentry"><span class="author"><span class="familyName">Ermis</span>, <span class="givenNames">U.</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Weis</span></span>, and <span class="author"><span class="givenNames">J. B.</span> <span class="familyName">Schulz</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">PML in a patient treated with fumaric acid</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">368</span>:<span class="pageFirst">1657</span>&#x2013;<span class="pageLast">1658</span>.</span></li><li class="bib" id="brb3362-bib-0029"><span class="citation" data-type="journal" id="brb3362-cit-0029" role="doc-biblioentry"><span class="author"><span class="familyName">Farez</span>, <span class="givenNames">M. F.</span></span>, <span class="author"><span class="givenNames">M. P.</span> <span class="familyName">Fiol</span></span>, <span class="author"><span class="givenNames">M. I.</span> <span class="familyName">Gaitan</span></span>, <span class="author"><span class="givenNames">F. J.</span> <span class="familyName">Quintana</span></span>, and <span class="author"><span class="givenNames">J.</span> <span class="familyName">Correale</span></span>. <span class="pubYear" data-year="2015">2015</span>. <span class="articleTitle">Sodium intake is associated with increased disease activity in multiple sclerosis</span>. <span class="journalTitle">J. Neurol. Neurosurg. Psychiatry</span> <span class="vol">86</span>:<span class="pageFirst">26</span>&#x2013;<span class="pageLast">31</span>.</span></li><li class="bib" id="brb3362-bib-0030"><span class="citation" data-type="other" id="brb3362-cit-0030" role="doc-biblioentry"><span class="groupName">FDA Drug Safety Communication</span>: <span class="otherTitle">FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)</span>. <span class="url"><a class="urlAnchor" href="http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm</a></span>, <span class="pubYear" data-year="2014">2014</span>. (Accessed January 8, 2015).</span></li><li class="bib" id="brb3362-bib-0031"><span class="citation" data-type="journal" id="brb3362-cit-0031" role="doc-biblioentry"><span class="author"><span class="familyName">Filippi</span>, <span class="givenNames">M.</span></span>, <span class="author"><span class="givenNames">M. A.</span> <span class="familyName">Horsfield</span></span>, <span class="author"><span class="givenNames">S. P.</span> <span class="familyName">Morrissey</span></span>, <span class="author"><span class="givenNames">D. G.</span> <span class="familyName">MacManus</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Rudge</span></span>, <span class="author"><span class="givenNames">W. I.</span> <span class="familyName">McDonald</span></span>, et&#xa0;al. <span class="pubYear" data-year="1994">1994</span>. <span class="articleTitle">Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis</span>. <span class="journalTitle">Neurology</span> <span class="vol">44</span>:<span class="pageFirst">635</span>&#x2013;<span class="pageLast">641</span>.</span></li><li class="bib" id="brb3362-bib-0032"><span class="citation" data-type="journal" id="brb3362-cit-0032" role="doc-biblioentry"><span class="author"><span class="familyName">Filippini</span>, <span class="givenNames">G.</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Del Giovane</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Vacchi</span></span>, <span class="author"><span class="givenNames">R.</span> <span class="familyName">D'Amico</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Di Pietrantonj</span></span>, <span class="author"><span class="givenNames">D.</span> <span class="familyName">Beecher</span></span>, et&#xa0;al. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Immunomodulators and immunosuppressants for multiple sclerosis: a network meta&#x2010;analysis</span>. <span class="journalTitle">Cochrane Database Syst. Rev.</span> <span class="vol">6</span>:<span class="pageFirst">CD008933</span>.</span></li><li class="bib" id="brb3362-bib-0033"><span class="citation" data-type="journal" id="brb3362-cit-0033" role="doc-biblioentry"><span class="author"><span class="familyName">Fox</span>, <span class="givenNames">E. J.</span></span> <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Management of worsening multiple sclerosis with mitoxantrone: a review</span>. <span class="journalTitle">Clin. Ther.</span> <span class="vol">28</span>:<span class="pageFirst">461</span>&#x2013;<span class="pageLast">474</span>.</span></li><li class="bib" id="brb3362-bib-0034"><span class="citation" data-type="journal" id="brb3362-cit-0034" role="doc-biblioentry"><span class="author"><span class="familyName">Fox</span>, <span class="givenNames">R. J.</span></span>, <span class="author"><span class="givenNames">D. H.</span> <span class="familyName">Miller</span></span>, <span class="author"><span class="givenNames">J. T.</span> <span class="familyName">Phillips</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Hutchinson</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Havrdova</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Kita</span></span>, et&#xa0;al. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Placebo&#x2010;controlled phase 3 study of oral BG&#x2010;12 or glatiramer in multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">367</span>:<span class="pageFirst">1087</span>&#x2013;<span class="pageLast">1097</span>.</span></li><li class="bib" id="brb3362-bib-0035"><span class="citation" data-type="journal" id="brb3362-cit-0035" role="doc-biblioentry"><span class="author"><span class="familyName">Fox</span>, <span class="givenNames">R. J.</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Kita</span></span>, <span class="author"><span class="givenNames">S. L.</span> <span class="familyName">Cohan</span></span>, <span class="author"><span class="givenNames">L. J.</span> <span class="familyName">Henson</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Zambrano</span></span>, <span class="author"><span class="givenNames">R. H.</span> <span class="familyName">Scannevin</span></span>, et&#xa0;al. <span class="pubYear" data-year="2014">2014</span>. <span class="articleTitle">BG&#x2010;12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety</span>. <span class="journalTitle">Curr. Med. Res. Opin.</span> <span class="vol">30</span>:<span class="pageFirst">251</span>&#x2013;<span class="pageLast">262</span>.</span></li><li class="bib" id="brb3362-bib-0036"><span class="citation" data-type="journal" id="brb3362-cit-0036" role="doc-biblioentry"><span class="author"><span class="familyName">Fragoso</span>, <span class="givenNames">Y. D.</span></span> <span class="pubYear" data-year="2014">2014</span>. <span class="articleTitle">Modifiable environmental factors in multiple sclerosis</span>. <span class="journalTitle">Arq. Neuropsiquiatr.</span> <span class="vol">72</span>:<span class="pageFirst">889</span>&#x2013;<span class="pageLast">894</span>.</span></li><li class="bib" id="brb3362-bib-0037"><span class="citation" data-type="journal" id="brb3362-cit-0037" role="doc-biblioentry"><span class="author"><span class="familyName">Frischer</span>, <span class="givenNames">J. M.</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Bramow</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Dal&#x2010;Bianco</span></span>, <span class="author"><span class="givenNames">C. F.</span> <span class="familyName">Lucchinetti</span></span>, <span class="author"><span class="givenNames">H.</span> <span class="familyName">Rauschka</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Schmidbauer</span></span>, et&#xa0;al. <span class="pubYear" data-year="2009">2009</span>. <span class="articleTitle">The relation between inflammation and neurodegeneration in multiple sclerosis brains</span>. <span class="journalTitle">Brain</span> <span class="vol">132</span>:<span class="pageFirst">1175</span>&#x2013;<span class="pageLast">1189</span>.</span></li><li class="bib" id="brb3362-bib-0038"><span class="citation" data-type="journal" id="brb3362-cit-0038" role="doc-biblioentry"><span class="author"><span class="familyName">Frohman</span>, <span class="givenNames">E. M.</span></span>, <span class="author"><span class="givenNames">M. K.</span> <span class="familyName">Racke</span></span>, and <span class="author"><span class="givenNames">C. S.</span> <span class="familyName">Raine</span></span>. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Multiple sclerosis&#x2013;the plaque and its pathogenesis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">354</span>:<span class="pageFirst">942</span>&#x2013;<span class="pageLast">955</span>.</span></li><li class="bib" id="brb3362-bib-0039"><span class="citation" data-type="journal" id="brb3362-cit-0039" role="doc-biblioentry"><span class="author"><span class="familyName">Fujinami</span>, <span class="givenNames">R. S.</span></span>, and <span class="author"><span class="givenNames">M. B.</span> <span class="familyName">Oldstone</span></span>. <span class="pubYear" data-year="1985">1985</span>. <span class="articleTitle">Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity</span>. <span class="journalTitle">Science</span> <span class="vol">230</span>:<span class="pageFirst">1043</span>&#x2013;<span class="pageLast">1045</span>.</span></li><li class="bib" id="brb3362-bib-0040"><span class="citation" data-type="journal" id="brb3362-cit-0040" role="doc-biblioentry"><span class="author"><span class="familyName">Geurts</span>, <span class="givenNames">J. J.</span></span>, and <span class="author"><span class="givenNames">F.</span> <span class="familyName">Barkhof</span></span>. <span class="pubYear" data-year="2008">2008</span>. <span class="articleTitle">Grey matter pathology in multiple sclerosis</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">7</span>:<span class="pageFirst">841</span>&#x2013;<span class="pageLast">851</span>.</span></li><li class="bib" id="brb3362-bib-0041"><span class="citation" data-type="journal" id="brb3362-cit-0041" role="doc-biblioentry"><span class="author"><span class="familyName">Gold</span>, <span class="givenNames">R.</span></span>, and <span class="author"><span class="givenNames">J. S.</span> <span class="familyName">Wolinsky</span></span>. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Pathophysiology of multiple sclerosis and the place of teriflunomide</span>. <span class="journalTitle">Acta Neurol. Scand.</span> <span class="vol">124</span>:<span class="pageFirst">75</span>&#x2013;<span class="pageLast">84</span>.</span></li><li class="bib" id="brb3362-bib-0042"><span class="citation" data-type="journal" id="brb3362-cit-0042" role="doc-biblioentry"><span class="author"><span class="familyName">Gold</span>, <span class="givenNames">R.</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Linington</span></span>, and <span class="author"><span class="givenNames">H.</span> <span class="familyName">Lassmann</span></span>. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70&#xa0;years of merits and culprits in experimental autoimmune encephalomyelitis research</span>. <span class="journalTitle">Brain</span> <span class="vol">129</span>:<span class="pageFirst">1953</span>&#x2013;<span class="pageLast">1971</span>.</span></li><li class="bib" id="brb3362-bib-0043"><span class="citation" data-type="journal" id="brb3362-cit-0043" role="doc-biblioentry"><span class="author"><span class="familyName">Gold</span>, <span class="givenNames">R.</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Kappos</span></span>, <span class="author"><span class="givenNames">D. L.</span> <span class="familyName">Arnold</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Bar&#x2010;Or</span></span>, <span class="author"><span class="givenNames">G.</span> <span class="familyName">Giovannoni</span></span>, <span class="author"><span class="givenNames">K.</span> <span class="familyName">Selmaj</span></span>, et&#xa0;al. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Placebo&#x2010;controlled phase 3 study of oral BG&#x2010;12 for relapsing multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">367</span>:<span class="pageFirst">1098</span>&#x2013;<span class="pageLast">1107</span>.</span></li><li class="bib" id="brb3362-bib-0044"><span class="citation" data-type="journal" id="brb3362-cit-0044" role="doc-biblioentry"><span class="author"><span class="familyName">Gran</span>, <span class="givenNames">B.</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Hemmer</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Vergelli</span></span>, <span class="author"><span class="givenNames">H. F.</span> <span class="familyName">McFarland</span></span>, and <span class="author"><span class="givenNames">R.</span> <span class="familyName">Martin</span></span>. <span class="pubYear" data-year="1999">1999</span>. <span class="articleTitle">Molecular mimicry and multiple sclerosis: degenerate T&#x2010;cell recognition and the induction of autoimmunity</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">45</span>:<span class="pageFirst">559</span>&#x2013;<span class="pageLast">567</span>.</span></li><li class="bib" id="brb3362-bib-0045"><span class="citation" data-type="journal" id="brb3362-cit-0045" role="doc-biblioentry"><span class="author"><span class="familyName">Gran</span>, <span class="givenNames">B.</span></span>, <span class="author"><span class="givenNames">L. R.</span> <span class="familyName">Tranquill</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Chen</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Bielekova</span></span>, <span class="author"><span class="givenNames">W.</span> <span class="familyName">Zhou</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Dhib&#x2010;Jalbut</span></span>, et&#xa0;al. <span class="pubYear" data-year="2000">2000</span>. <span class="articleTitle">Mechanisms of immunomodulation by glatiramer acetate</span>. <span class="journalTitle">Neurology</span> <span class="vol">55</span>:<span class="pageFirst">1704</span>&#x2013;<span class="pageLast">1714</span>.</span></li><li class="bib" id="brb3362-bib-0046"><span class="citation" data-type="journal" id="brb3362-cit-0046" role="doc-biblioentry"><span class="author"><span class="familyName">Hafler</span>, <span class="givenNames">D. A.</span></span>, <span class="author"><span class="givenNames">J. M.</span> <span class="familyName">Slavik</span></span>, <span class="author"><span class="givenNames">D. E.</span> <span class="familyName">Anderson</span></span>, <span class="author"><span class="givenNames">K. C.</span> <span class="familyName">O'Connor</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyNamePrefix">De</span> <span class="familyName">Jager</span></span>, and <span class="author"><span class="givenNames">C.</span> <span class="familyName">Baecher&#x2010;Allan</span></span>. <span class="pubYear" data-year="2005">2005</span>. <span class="articleTitle">Multiple sclerosis</span>. <span class="journalTitle">Immunol. Rev.</span> <span class="vol">204</span>:<span class="pageFirst">208</span>&#x2013;<span class="pageLast">231</span>.</span></li><li class="bib" id="brb3362-bib-0047"><span class="citation" data-type="journal" id="brb3362-cit-0047" role="doc-biblioentry"><span class="author"><span class="familyName">Hafler</span>, <span class="givenNames">D. A.</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Compston</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Sawcer</span></span>, <span class="author"><span class="givenNames">E. S.</span> <span class="familyName">Lander</span></span>, <span class="author"><span class="givenNames">M. J.</span> <span class="familyName">Daly</span></span>, <span class="author"><span class="givenNames">P. L.</span> <span class="familyName">De Jager</span></span>, et&#xa0;al. <span class="pubYear" data-year="2007">2007</span>. <span class="articleTitle">Risk alleles for multiple sclerosis identified by a genome wide study</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">357</span>:<span class="pageFirst">851</span>&#x2013;<span class="pageLast">862</span>.</span></li><li class="bib" id="brb3362-bib-0048"><span class="citation" data-type="journal" id="brb3362-cit-0048" role="doc-biblioentry"><span class="author"><span class="familyName">Hauser</span>, <span class="givenNames">S. L.</span></span>, <span class="author"><span class="givenNames">A. K.</span> <span class="familyName">Bhan</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Gilles</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Kemp</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Kerr</span></span>, and <span class="author"><span class="givenNames">H. L.</span> <span class="familyName">Weiner</span></span>. <span class="pubYear" data-year="1986">1986</span>. <span class="articleTitle">Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">19</span>:<span class="pageFirst">578</span>&#x2013;<span class="pageLast">587</span>.</span></li><li class="bib" id="brb3362-bib-0049"><span class="citation" data-type="journal" id="brb3362-cit-0049" role="doc-biblioentry"><span class="author"><span class="familyName">Hemmer</span>, <span class="givenNames">B.</span></span>, <span class="author"><span class="givenNames">J. J.</span> <span class="familyName">Archelos</span></span>, and <span class="author"><span class="givenNames">H. P.</span> <span class="familyName">Hartung</span></span>. <span class="pubYear" data-year="2002">2002</span>. <span class="articleTitle">New concepts in the immunopathogenesis of multiple sclerosis</span>. <span class="journalTitle">Nat. Rev. Neurosci.</span> <span class="vol">3</span>:<span class="pageFirst">291</span>&#x2013;<span class="pageLast">301</span>.</span></li><li class="bib" id="brb3362-bib-0050"><span class="citation" data-type="journal" id="brb3362-cit-0050" role="doc-biblioentry"><span class="author"><span class="familyName">Howell</span>, <span class="givenNames">O. W.</span></span>, <span class="author"><span class="givenNames">C. A.</span> <span class="familyName">Reeves</span></span>, <span class="author"><span class="givenNames">R.</span> <span class="familyName">Nicholas</span></span>, <span class="author"><span class="givenNames">D.</span> <span class="familyName">Carassiti</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Radotra</span></span>, <span class="author"><span class="givenNames">S. M.</span> <span class="familyName">Gentleman</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis</span>. <span class="journalTitle">Brain</span> <span class="vol">134</span>:<span class="pageFirst">2755</span>&#x2013;<span class="pageLast">2771</span>.</span></li><li class="bib" id="brb3362-bib-0052"><span class="citation" data-type="journal" id="brb3362-cit-0052" role="doc-biblioentry"><span class="author"><span class="familyName">Ingle</span>, <span class="givenNames">G. T.</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Sastre&#x2010;Garriga</span></span>, <span class="author"><span class="givenNames">D. H.</span> <span class="familyName">Miller</span></span>, and <span class="author"><span class="givenNames">A. J.</span> <span class="familyName">Thompson</span></span>. <span class="pubYear" data-year="2005">2005</span>. <span class="articleTitle">Is inflammation important in early PPMS? a longitudinal MRI study</span>. <span class="journalTitle">J. Neurol. Neurosurg. Psychiatry</span> <span class="vol">76</span>:<span class="pageFirst">1255</span>&#x2013;<span class="pageLast">1258</span>.</span></li><li class="bib" id="brb3362-bib-0053"><span class="citation" data-type="journal" id="brb3362-cit-0053" role="doc-biblioentry"><span class="author"><span class="familyName">Inglese</span>, <span class="givenNames">M.</span></span> <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Multiple sclerosis: new insights and trends</span>. <span class="journalTitle">AJNR Am. J. Neuroradiol.</span> <span class="vol">27</span>:<span class="pageFirst">954</span>&#x2013;<span class="pageLast">957</span>.</span></li><li class="bib" id="brb3362-bib-0054"><span class="citation" data-type="journal" id="brb3362-cit-0054" role="doc-biblioentry"><span class="author"><span class="familyName">Kantarci</span>, <span class="givenNames">O. H.</span></span> <span class="pubYear" data-year="2008">2008</span>. <span class="articleTitle">Genetics and natural history of multiple sclerosis</span>. <span class="journalTitle">Semin. Neurol.</span> <span class="vol">28</span>:<span class="pageFirst">7</span>&#x2013;<span class="pageLast">16</span>.</span></li><li class="bib" id="brb3362-bib-0055"><span class="citation" data-type="journal" id="brb3362-cit-0055" role="doc-biblioentry"><span class="author"><span class="familyName">Kappos</span>, <span class="givenNames">L.</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Weinshenker</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Pozzilli</span></span>, <span class="author"><span class="givenNames">A. J.</span> <span class="familyName">Thompson</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Dahlke</span></span>, <span class="author"><span class="givenNames">K.</span> <span class="familyName">Beckmann</span></span>, et&#xa0;al. <span class="pubYear" data-year="2004">2004</span>. <span class="articleTitle">Interferon beta&#x2010;1b in secondary progressive MS: a combined analysis of the two trials</span>. <span class="journalTitle">Neurology</span> <span class="vol">63</span>:<span class="pageFirst">1779</span>&#x2013;<span class="pageLast">1787</span>.</span></li><li class="bib" id="brb3362-bib-0056"><span class="citation" data-type="journal" id="brb3362-cit-0056" role="doc-biblioentry"><span class="author"><span class="familyName">Kappos</span>, <span class="givenNames">L.</span></span>, <span class="author"><span class="givenNames">E. W.</span> <span class="familyName">Radue</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">O'Connor</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Polman</span></span>, <span class="author"><span class="givenNames">R.</span> <span class="familyName">Hohlfeld</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Calabresi</span></span>, et&#xa0;al. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">A placebo&#x2010;controlled trial of oral fingolimod in relapsing multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">362</span>:<span class="pageFirst">387</span>&#x2013;<span class="pageLast">401</span>.</span></li><li class="bib" id="brb3362-bib-0057"><span class="citation" data-type="journal" id="brb3362-cit-0057" role="doc-biblioentry"><span class="author"><span class="familyName">Karussis</span>, <span class="givenNames">D.</span></span> <span class="pubYear" data-year="2014">2014</span>. <span class="articleTitle">The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review</span>. <span class="journalTitle">J. Autoimmun.</span> <span class="vol">48&#x2013;49</span>:<span class="pageFirst">134</span>&#x2013;<span class="pageLast">142</span>.</span></li><li class="bib" id="brb3362-bib-0058"><span class="citation" data-type="journal" id="brb3362-cit-0058" role="doc-biblioentry"><span class="author"><span class="familyName">Kister</span>, <span class="givenNames">I.</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Chamot</span></span>, <span class="author"><span class="givenNames">A. R.</span> <span class="familyName">Salter</span></span>, <span class="author"><span class="givenNames">G. R.</span> <span class="familyName">Cutter</span></span>, <span class="author"><span class="givenNames">T. E.</span> <span class="familyName">Bacon</span></span>, and <span class="author"><span class="givenNames">J.</span> <span class="familyName">Herbert</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Disability in multiple sclerosis: a reference for patients and clinicians</span>. <span class="journalTitle">Neurology</span> <span class="vol">80</span>:<span class="pageFirst">1018</span>&#x2013;<span class="pageLast">1024</span>.</span></li><li class="bib" id="brb3362-bib-0059"><span class="citation" data-type="journal" id="brb3362-cit-0059" role="doc-biblioentry"><span class="author"><span class="familyName">Kleinewietfeld</span>, <span class="givenNames">M.</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Manzel</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Titze</span></span>, <span class="author"><span class="givenNames">H.</span> <span class="familyName">Kvakan</span></span>, <span class="author"><span class="givenNames">N.</span> <span class="familyName">Yosef</span></span>, <span class="author"><span class="givenNames">R. A.</span> <span class="familyName">Linker</span></span>, et&#xa0;al. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells</span>. <span class="journalTitle">Nature</span> <span class="vol">496</span>:<span class="pageFirst">518</span>&#x2013;<span class="pageLast">522</span>.</span></li><li class="bib" id="brb3362-bib-0060"><span class="citation" data-type="journal" id="brb3362-cit-0060" role="doc-biblioentry"><span class="author"><span class="familyName">La Mantia</span>, <span class="givenNames">L.</span></span>, <span class="author"><span class="givenNames">L. M.</span> <span class="familyName">Munari</span></span>, and <span class="author"><span class="givenNames">R.</span> <span class="familyName">Lovati</span></span>. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">Glatiramer acetate for multiple sclerosis</span>. <span class="journalTitle">Cochrane Database Syst. Rev.</span> <span class="pageFirst">CD004678</span>.</span></li><li class="bib" id="brb3362-bib-0061"><span class="citation" data-type="journal" id="brb3362-cit-0061" role="doc-biblioentry"><span class="author"><span class="familyName">Lindsey</span>, <span class="givenNames">J. W.</span></span>, <span class="author"><span class="givenNames">K.</span> <span class="familyName">Haden&#x2010;Pinneri</span></span>, <span class="author"><span class="givenNames">N. B.</span> <span class="familyName">Memon</span></span>, and <span class="author"><span class="givenNames">L. M.</span> <span class="familyName">Buja</span></span>. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Sudden unexpected death on fingolimod</span>. <span class="journalTitle">Mult. Scler.</span> <span class="vol">18</span>:<span class="pageFirst">1507</span>&#x2013;<span class="pageLast">1508</span>.</span></li><li class="bib" id="brb3362-bib-0062"><span class="citation" data-type="journal" id="brb3362-cit-0062" role="doc-biblioentry"><span class="author"><span class="familyName">Link</span>, <span class="givenNames">H.</span></span>, and <span class="author"><span class="givenNames">Y. M.</span> <span class="familyName">Huang</span></span>. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness</span>. <span class="journalTitle">J. Neuroimmunol.</span> <span class="vol">180</span>:<span class="pageFirst">17</span>&#x2013;<span class="pageLast">28</span>.</span></li><li class="bib" id="brb3362-bib-0063"><span class="citation" data-type="journal" id="brb3362-cit-0063" role="doc-biblioentry"><span class="author"><span class="familyName">Linker</span>, <span class="givenNames">R. A.</span></span>, <span class="author"><span class="givenNames">D. H.</span> <span class="familyName">Lee</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Ryan</span></span>, <span class="author"><span class="givenNames">A. M.</span> <span class="familyName">van Dam</span></span>, <span class="author"><span class="givenNames">R.</span> <span class="familyName">Conrad</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Bista</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation&#xa0;of the Nrf2 antioxidant pathway</span>. <span class="journalTitle">Brain</span> <span class="vol">134</span>:<span class="pageFirst">678</span>&#x2013;<span class="pageLast">692</span>.</span></li><li class="bib" id="brb3362-bib-0064"><span class="citation" data-type="journal" id="brb3362-cit-0064" role="doc-biblioentry"><span class="author"><span class="familyName">Lublin</span>, <span class="givenNames">F. D.</span></span>, and <span class="author"><span class="givenNames">S. C.</span> <span class="familyName">Reingold</span></span>. <span class="pubYear" data-year="1996">1996</span>. <span class="articleTitle">Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis</span>. <span class="journalTitle">Neurology</span> <span class="vol">46</span>:<span class="pageFirst">907</span>&#x2013;<span class="pageLast">911</span>.</span></li><li class="bib" id="brb3362-bib-0065"><span class="citation" data-type="journal" id="brb3362-cit-0065" role="doc-biblioentry"><span class="author"><span class="familyName">Lublin</span>, <span class="givenNames">F. D.</span></span>, <span class="author"><span class="givenNames">S. C.</span> <span class="familyName">Reingold</span></span>, <span class="author"><span class="givenNames">J. A.</span> <span class="familyName">Cohen</span></span>, <span class="author"><span class="givenNames">G. R.</span> <span class="familyName">Cutter</span></span>, <span class="author"><span class="givenNames">P. S.</span> <span class="familyName">S&#xf8;rensen</span></span>, <span class="author"><span class="givenNames">A. J.</span> <span class="familyName">Thompson</span></span> et&#xa0;al. <span class="pubYear" data-year="2014">2014</span>. <span class="articleTitle">Defining the clinical course of multiple sclerosis: the 2013 revisions</span>. <span class="journalTitle">Neurology</span> <span class="vol">83</span>:<span class="pageFirst">278</span>&#x2013;<span class="pageLast">286</span>.</span></li><li class="bib" id="brb3362-bib-0066"><span class="citation" data-type="journal" id="brb3362-cit-0066" role="doc-biblioentry"><span class="author"><span class="familyName">Lucchinetti</span>, <span class="givenNames">C.</span></span>, <span class="author"><span class="givenNames">W.</span> <span class="familyName">Bruck</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Parisi</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Scheithauer</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Rodriguez</span></span>, and <span class="author"><span class="givenNames">H.</span> <span class="familyName">Lassmann</span></span>. <span class="pubYear" data-year="2000">2000</span>. <span class="articleTitle">Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">47</span>:<span class="pageFirst">707</span>&#x2013;<span class="pageLast">717</span>.</span></li><li class="bib" id="brb3362-bib-0067"><span class="citation" data-type="journal" id="brb3362-cit-0067" role="doc-biblioentry"><span class="author"><span class="familyName">Lucchinetti</span>, <span class="givenNames">C. F.</span></span>, <span class="author"><span class="givenNames">R. H.</span> <span class="familyName">Gavrilova</span></span>, <span class="author"><span class="givenNames">I.</span> <span class="familyName">Metz</span></span>, <span class="author"><span class="givenNames">J. E.</span> <span class="familyName">Parisi</span></span>, <span class="author"><span class="givenNames">B. W.</span> <span class="familyName">Scheithauer</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Weigand</span></span>, et&#xa0;al. <span class="pubYear" data-year="2008">2008</span>. <span class="articleTitle">Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis</span>. <span class="journalTitle">Brain</span> <span class="vol">131</span>:<span class="pageFirst">1759</span>&#x2013;<span class="pageLast">1775</span>.</span></li><li class="bib" id="brb3362-bib-0068"><span class="citation" data-type="journal" id="brb3362-cit-0068" role="doc-biblioentry"><span class="author"><span class="familyName">Lucchinetti</span>, <span class="givenNames">C. F.</span></span>, <span class="author"><span class="givenNames">B. F.</span> <span class="familyName">Popescu</span></span>, <span class="author"><span class="givenNames">R. F.</span> <span class="familyName">Bunyan</span></span>, <span class="author"><span class="givenNames">N. M.</span> <span class="familyName">Moll</span></span>, <span class="author"><span class="givenNames">S. F.</span> <span class="familyName">Roemer</span></span>, <span class="author"><span class="givenNames">H.</span> <span class="familyName">Lassmann</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Inflammatory cortical demyelination in early multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">365</span>:<span class="pageFirst">2188</span>&#x2013;<span class="pageLast">2197</span>.</span></li><li class="bib" id="brb3362-bib-0069"><span class="citation" data-type="journal" id="brb3362-cit-0069" role="doc-biblioentry"><span class="author"><span class="familyName">Mayr</span>, <span class="givenNames">W. T.</span></span>, <span class="author"><span class="givenNames">S. J.</span> <span class="familyName">Pittock</span></span>, <span class="author"><span class="givenNames">R. L.</span> <span class="familyName">McClelland</span></span>, <span class="author"><span class="givenNames">N. W.</span> <span class="familyName">Jorgensen</span></span>, <span class="author"><span class="givenNames">J. H.</span> <span class="familyName">Noseworthy</span></span>, and <span class="author"><span class="givenNames">M.</span> <span class="familyName">Rodriguez</span></span>. <span class="pubYear" data-year="2003">2003</span>. <span class="articleTitle">Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985&#x2013;2000</span>. <span class="journalTitle">Neurology</span> <span class="vol">61</span>:<span class="pageFirst">1373</span>&#x2013;<span class="pageLast">1377</span>.</span></li><li class="bib" id="brb3362-bib-0070"><span class="citation" data-type="journal" id="brb3362-cit-0070" role="doc-biblioentry"><span class="author"><span class="familyName">Miller</span>, <span class="givenNames">D. H.</span></span>, and <span class="author"><span class="givenNames">S. M.</span> <span class="familyName">Leary</span></span>. <span class="pubYear" data-year="2007">2007</span>. <span class="articleTitle">Primary&#x2010;progressive multiple sclerosis</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">6</span>:<span class="pageFirst">903</span>&#x2013;<span class="pageLast">912</span>.</span></li><li class="bib" id="brb3362-bib-0071"><span class="citation" data-type="journal" id="brb3362-cit-0071" role="doc-biblioentry"><span class="author"><span class="familyName">Miller</span>, <span class="givenNames">S. D.</span></span>, <span class="author"><span class="givenNames">C. L.</span> <span class="familyName">Vanderlugt</span></span>, <span class="author"><span class="givenNames">W. S.</span> <span class="familyName">Begolka</span></span>, <span class="author"><span class="givenNames">W.</span> <span class="familyName">Pao</span></span>, <span class="author"><span class="givenNames">R. L.</span> <span class="familyName">Yauch</span></span>, <span class="author"><span class="givenNames">K. L.</span> <span class="familyName">Neville</span></span>, et&#xa0;al. <span class="pubYear" data-year="1997">1997</span>. <span class="articleTitle">Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading</span>. <span class="journalTitle">Nat. Med.</span> <span class="vol">3</span>:<span class="pageFirst">1133</span>&#x2013;<span class="pageLast">1136</span>.</span></li><li class="bib" id="brb3362-bib-0072"><span class="citation" data-type="journal" id="brb3362-cit-0072" role="doc-biblioentry"><span class="author"><span class="familyName">Miller</span>, <span class="givenNames">D. H.</span></span>, <span class="author"><span class="givenNames">O. A.</span> <span class="familyName">Khan</span></span>, <span class="author"><span class="givenNames">W. A.</span> <span class="familyName">Sheremata</span></span>, <span class="author"><span class="givenNames">L. D.</span> <span class="familyName">Blumhardt</span></span>, <span class="author"><span class="givenNames">G. P. A.</span> <span class="familyName">Rice</span></span>, <span class="author"><span class="givenNames">M. A.</span> <span class="familyName">Libonati</span></span>, et&#xa0;al. <span class="pubYear" data-year="2003">2003</span>. <span class="articleTitle">A controlled trial of natalizumab for relapsing multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">348</span>:<span class="pageFirst">15</span>&#x2013;<span class="pageLast">23</span>.</span></li><li class="bib" id="brb3362-bib-0073"><span class="citation" data-type="journal" id="brb3362-cit-0073" role="doc-biblioentry"><span class="author"><span class="familyName">Miller</span>, <span class="givenNames">D.</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Barkhof</span></span>, <span class="author"><span class="givenNames">X.</span> <span class="familyName">Montalban</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Thompson</span></span>, and <span class="author"><span class="givenNames">M.</span> <span class="familyName">Filippi</span></span>. <span class="pubYear" data-year="2005">2005</span>. <span class="articleTitle">Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">4</span>:<span class="pageFirst">281</span>&#x2013;<span class="pageLast">288</span>.</span></li><li class="bib" id="brb3362-bib-0500"><span class="citation" data-type="journal" id="brb3362-cit-0500" role="doc-biblioentry"><span class="author"><span class="familyName">Montalban</span>, <span class="givenNames">X.</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Tintore</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Swanton</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Barkhof</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Fazekas</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Filippi</span></span>, et al. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">MRI criteria for MS in patients with clinically isolated syndromes</span>. <span class="journalTitle">Neurology</span> <span class="vol">74</span>:<span class="pageFirst">427</span>&#x2013;<span class="pageLast">434</span>.</span></li><li class="bib" id="brb3362-bib-0074"><span class="citation" data-type="journal" id="brb3362-cit-0074" role="doc-biblioentry"><span class="author"><span class="familyName">Munger</span>, <span class="givenNames">K. L.</span></span>, <span class="author"><span class="givenNames">S. M.</span> <span class="familyName">Zhang</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">O'Reilly</span></span>, <span class="author"><span class="givenNames">M. A.</span> <span class="familyName">Hern&#xe1;n</span></span>, <span class="author"><span class="givenNames">M. J.</span> <span class="familyName">Olek</span></span>, <span class="author"><span class="givenNames">W. C.</span> <span class="familyName">Willett</span></span>, et&#xa0;al. <span class="pubYear" data-year="2004">2004</span>. <span class="articleTitle">Vitamin D intake and incidence of multiple sclerosis</span>. <span class="journalTitle">Neurology</span> <span class="vol">62</span>:<span class="pageFirst">60</span>&#x2013;<span class="pageLast">65</span>.</span></li><li class="bib" id="brb3362-bib-0075"><span class="citation" data-type="journal" id="brb3362-cit-0075" role="doc-biblioentry"><span class="author"><span class="familyName">Munger</span>, <span class="givenNames">K. L.</span></span>, <span class="author"><span class="givenNames">L. I.</span> <span class="familyName">Levin</span></span>, <span class="author"><span class="givenNames">B. W.</span> <span class="familyName">Hollis</span></span>, <span class="author"><span class="givenNames">N. S.</span> <span class="familyName">Howard</span></span>, and <span class="author"><span class="givenNames">A.</span> <span class="familyName">Ascherio</span></span>. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Serum 25&#x2010;hydroxyvitamin D levels and risk of multiple sclerosis</span>. <span class="journalTitle">JAMA</span> <span class="vol">296</span>:<span class="pageFirst">2832</span>&#x2013;<span class="pageLast">2838</span>.</span></li><li class="bib" id="brb3362-bib-0076"><span class="citation" data-type="journal" id="brb3362-cit-0076" role="doc-biblioentry"><span class="author"><span class="familyName">Naismith</span>, <span class="givenNames">R. T.</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Piccio</span></span>, <span class="author"><span class="givenNames">J. A.</span> <span class="familyName">Lyons</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Lauber</span></span>, <span class="author"><span class="givenNames">N. T.</span> <span class="familyName">Tutlam</span></span>, <span class="author"><span class="givenNames">B. J.</span> <span class="familyName">Parks</span></span>, et&#xa0;al. <span class="pubYear" data-year="2010">2010</span>. <span class="articleTitle">Rituximab add&#x2010;on therapy for breakthrough relapsing multiple sclerosis: a 52&#x2010;week phase II trial</span>. <span class="journalTitle">Neurology</span> <span class="vol">74</span>:<span class="pageFirst">1860</span>&#x2013;<span class="pageLast">1867</span>.</span></li><li class="bib" id="brb3362-bib-0077"><span class="citation" data-type="journal" id="brb3362-cit-0077" role="doc-biblioentry"><span class="author"><span class="familyName">O'Connor</span>, <span class="givenNames">K. C.</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Bar&#x2010;Or</span></span>, and <span class="author"><span class="givenNames">D. A.</span> <span class="familyName">Hafler</span></span>. <span class="pubYear" data-year="2001">2001</span>. <span class="articleTitle">The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis</span>. <span class="journalTitle">J. Clin. Immunol.</span> <span class="vol">21</span>:<span class="pageFirst">81</span>&#x2013;<span class="pageLast">92</span>.</span></li><li class="bib" id="brb3362-bib-0078"><span class="citation" data-type="journal" id="brb3362-cit-0078" role="doc-biblioentry"><span class="author"><span class="familyName">O'Connor</span>, <span class="givenNames">P.</span></span>, <span class="author"><span class="givenNames">J. S.</span> <span class="familyName">Wolinsky</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Confavreux</span></span>, <span class="author"><span class="givenNames">G.</span> <span class="familyName">Comi</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Kappos</span></span>, <span class="author"><span class="givenNames">T. P.</span> <span class="familyName">Olsson</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Randomized trial of oral teriflunomide for relapsing multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">365</span>:<span class="pageFirst">1293</span>&#x2013;<span class="pageLast">1303</span>.</span></li><li class="bib" id="brb3362-bib-0079"><span class="citation" data-type="journal" id="brb3362-cit-0079" role="doc-biblioentry"><span class="author"><span class="familyName">Oh</span>, <span class="givenNames">J.</span></span>, and <span class="author"><span class="givenNames">P. W.</span> <span class="familyName">O'Connor</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">An update of teriflunomide for treatment of multiple sclerosis</span>. <span class="journalTitle">Ther. Clin. Risk Manag.</span> <span class="vol">9</span>:<span class="pageFirst">177</span>&#x2013;<span class="pageLast">190</span>.</span></li><li class="bib" id="brb3362-bib-0080"><span class="citation" data-type="journal" id="brb3362-cit-0080" role="doc-biblioentry"><span class="author"><span class="familyNamePrefix">van</span> <span class="familyName">Oosten</span>, <span class="givenNames">B. W.</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Killestein</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Barkhof</span></span>, <span class="author"><span class="givenNames">C. H.</span> <span class="familyName">Polman</span></span>, and <span class="author"><span class="givenNames">M. P.</span> <span class="familyName">Wattjes</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">PML in a patient treated with dimethyl fumarate from a compounding pharmacy</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">368</span>:<span class="pageFirst">1658</span>&#x2013;<span class="pageLast">1659</span>.</span></li><li class="bib" id="brb3362-bib-0081"><span class="citation" data-type="journal" id="brb3362-cit-0081" role="doc-biblioentry"><span class="author"><span class="familyName">Orton</span>, <span class="givenNames">S. M.</span></span>, <span class="author"><span class="givenNames">B. M.</span> <span class="familyName">Herrera</span></span>, <span class="author"><span class="givenNames">I. M.</span> <span class="familyName">Yee</span></span>, <span class="author"><span class="givenNames">W.</span> <span class="familyName">Valdar</span></span>, <span class="author"><span class="givenNames">S. V.</span> <span class="familyName">Ramagopalan</span></span>, <span class="author"><span class="givenNames">A. D.</span> <span class="familyName">Sadovnick</span></span>, et&#xa0;al. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Sex ratio of multiple sclerosis in Canada: a longitudinal study</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">5</span>:<span class="pageFirst">932</span>&#x2013;<span class="pageLast">936</span>.</span></li><li class="bib" id="brb3362-bib-0082"><span class="citation" data-type="journal" id="brb3362-cit-0082" role="doc-biblioentry"><span class="author"><span class="familyName">Pelletier</span>, <span class="givenNames">D.</span></span>, and <span class="author"><span class="givenNames">D. A.</span> <span class="familyName">Hafler</span></span>. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Fingolimod for multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">366</span>:<span class="pageFirst">339</span>&#x2013;<span class="pageLast">347</span>.</span></li><li class="bib" id="brb3362-bib-0083"><span class="citation" data-type="journal" id="brb3362-cit-0083" role="doc-biblioentry"><span class="author"><span class="familyName">Polman</span>, <span class="givenNames">C. H.</span></span>, <span class="author"><span class="givenNames">P. W.</span> <span class="familyName">O'Connor</span></span>, <span class="author"><span class="givenNames">E.</span> <span class="familyName">Havrdova</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Hutchinson</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Kappos</span></span>, <span class="author"><span class="givenNames">D. H.</span> <span class="familyName">Miller</span></span>, et&#xa0;al. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">A randomized, placebo&#x2010;controlled trial of natalizumab for relapsing multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">354</span>:<span class="pageFirst">899</span>&#x2013;<span class="pageLast">910</span>.</span></li><li class="bib" id="brb3362-bib-0084"><span class="citation" data-type="journal" id="brb3362-cit-0084" role="doc-biblioentry"><span class="author"><span class="familyName">Polman</span>, <span class="givenNames">C. H.</span></span>, <span class="author"><span class="givenNames">S. C.</span> <span class="familyName">Reingold</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Banwell</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Clanet</span></span>, <span class="author"><span class="givenNames">J. A.</span> <span class="familyName">Cohen</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Filippi</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">69</span>:<span class="pageFirst">292</span>&#x2013;<span class="pageLast">302</span>.</span></li><li class="bib" id="brb3362-bib-0085"><span class="citation" data-type="journal" id="brb3362-cit-0085" role="doc-biblioentry"><span class="author"><span class="familyName">Popescu</span>, <span class="givenNames">B. F.</span></span>, and <span class="author"><span class="givenNames">C. F.</span> <span class="familyName">Lucchinetti</span></span>. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Pathology of demyelinating diseases</span>. <span class="journalTitle">Annu. Rev. Pathol.</span> <span class="vol">7</span>:<span class="pageFirst">185</span>&#x2013;<span class="pageLast">217</span>.</span></li><li class="bib" id="brb3362-bib-0086"><span class="citation" data-type="journal" id="brb3362-cit-0086" role="doc-biblioentry"><span class="author"><span class="familyName">Prineas</span>, <span class="givenNames">J. W.</span></span>, <span class="author"><span class="givenNames">E. E.</span> <span class="familyName">Kwon</span></span>, <span class="author"><span class="givenNames">E. S.</span> <span class="familyName">Cho</span></span>, <span class="author"><span class="givenNames">L. R.</span> <span class="familyName">Sharer</span></span>, <span class="author"><span class="givenNames">M. H.</span> <span class="familyName">Barnett</span></span>, <span class="author"><span class="givenNames">E. L.</span> <span class="familyName">Oleszak</span></span>, et&#xa0;al. <span class="pubYear" data-year="2001">2001</span>. <span class="articleTitle">Immunopathology of secondary&#x2010;progressive multiple sclerosis</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">50</span>:<span class="pageFirst">646</span>&#x2013;<span class="pageLast">657</span>.</span></li><li class="bib" id="brb3362-bib-0087"><span class="citation" data-type="journal" id="brb3362-cit-0087" role="doc-biblioentry"><span class="author"><span class="familyName">Ransohoff</span>, <span class="givenNames">R. M.</span></span> <span class="pubYear" data-year="2007">2007</span>. <span class="articleTitle">Natalizumab for multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">356</span>:<span class="pageFirst">2622</span>&#x2013;<span class="pageLast">2629</span>.</span></li><li class="bib" id="brb3362-bib-0088"><span class="citation" data-type="journal" id="brb3362-cit-0088" role="doc-biblioentry"><span class="author"><span class="familyName">Rudick</span>, <span class="givenNames">R. A.</span></span>, <span class="author"><span class="givenNames">J. A.</span> <span class="familyName">Cohen</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Weinstock&#x2010;Guttman</span></span>, <span class="author"><span class="givenNames">R. P.</span> <span class="familyName">Kinkel</span></span>, and <span class="author"><span class="givenNames">R. M.</span> <span class="familyName">Ransohoff</span></span>. <span class="pubYear" data-year="1997">1997</span>. <span class="articleTitle">Management of multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">337</span>:<span class="pageFirst">1604</span>&#x2013;<span class="pageLast">1611</span>.</span></li><li class="bib" id="brb3362-bib-0089"><span class="citation" data-type="journal" id="brb3362-cit-0089" role="doc-biblioentry"><span class="author"><span class="familyName">Ruggieri</span>, <span class="givenNames">M.</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Avolio</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Livrea</span></span>, and <span class="author"><span class="givenNames">M.</span> <span class="familyName">Trojano</span></span>. <span class="pubYear" data-year="2007">2007</span>. <span class="articleTitle">Glatiramer acetate in multiple sclerosis: a review</span>. <span class="journalTitle">CNS Drug Rev.</span> <span class="vol">13</span>:<span class="pageFirst">178</span>&#x2013;<span class="pageLast">191</span>.</span></li><li class="bib" id="brb3362-bib-0090"><span class="citation" data-type="journal" id="brb3362-cit-0090" role="doc-biblioentry"><span class="author"><span class="familyName">Samson</span>, <span class="givenNames">K.</span></span> <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">PML in suspected MS patient taking Fingolimod Raises FDA concerns</span>. <span class="journalTitle">Neurology Today</span> <span class="vol">13</span>:<span class="pageFirst">37</span>.</span></li><li class="bib" id="brb3362-bib-0091"><span class="citation" data-type="journal" id="brb3362-cit-0091" role="doc-biblioentry"><span class="author"><span class="familyName">Sawcer</span>, <span class="givenNames">S.</span></span>, <span class="author"><span class="givenNames">G.</span> <span class="familyName">Hellenthal</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Pirinen</span></span>, <span class="author"><span class="givenNames">C. C.</span> <span class="familyName">Spencer</span></span>, <span class="author"><span class="givenNames">N. A.</span> <span class="familyName">Patsopoulos</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Moutsianas</span></span>, et&#xa0;al. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Genetic risk and a primary role for cell&#x2010;mediated immune mechanisms in multiple sclerosis</span>. <span class="journalTitle">Nature</span> <span class="vol">476</span>:<span class="pageFirst">214</span>&#x2013;<span class="pageLast">219</span>.</span></li><li class="bib" id="brb3362-bib-0092"><span class="citation" data-type="journal" id="brb3362-cit-0092" role="doc-biblioentry"><span class="author"><span class="familyName">Selter</span>, <span class="givenNames">C. R.</span></span>, and <span class="author"><span class="givenNames">B.</span> <span class="familyName">Hemmer</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Update on immunopathogenesis and immunotherapy in multiple sclerosis</span>. <span class="journalTitle">Immuno. Targets Therapy</span> <span class="vol">2</span>:<span class="pageFirst">21</span>&#x2013;<span class="pageLast">30</span>.</span></li><li class="bib" id="brb3362-bib-0093"><span class="citation" data-type="journal" id="brb3362-cit-0093" role="doc-biblioentry"><span class="author"><span class="familyName">Simpson</span>, <span class="givenNames">S.</span> <span class="nameSuffix">Jr</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Blizzard</span></span>, <span class="author"><span class="givenNames">P.</span> <span class="familyName">Otahal</span></span>, <span class="author"><span class="givenNames">I.</span> <span class="familyNamePrefix">Van der</span> <span class="familyName">Mei</span></span>, and <span class="author"><span class="givenNames">B.</span> <span class="familyName">Taylor</span></span>. <span class="pubYear" data-year="2011">2011</span>. <span class="articleTitle">Latitude is significantly associated with the prevalence of multiple sclerosis: a meta&#x2010;analysis</span>. <span class="journalTitle">J. Neurol. Neurosurg. Psychiatry</span> <span class="vol">82</span>:<span class="pageFirst">1132</span>&#x2013;<span class="pageLast">1141</span>.</span></li><li class="bib" id="brb3362-bib-0094"><span class="citation" data-type="other" id="brb3362-cit-0094" role="doc-biblioentry"><span class="author"><span class="familyName">Sobel</span>, <span class="givenNames">R.</span></span>, and <span class="author"><span class="givenNames">W.</span> <span class="familyName">Moore</span></span>. <span class="pubYear" data-year="2008">2008</span>. Demyelinating diseases. Greenfield's neuropathology, <span class="publisherLoc">London, UK</span>: <span class="publisherName">Oxford Univ. Press</span> <span class="vol">2</span>:<span class="pageFirst">1513</span>&#x2013;<span class="pageLast">1608</span>.</span></li><li class="bib" id="brb3362-bib-0095"><span class="citation" data-type="journal" id="brb3362-cit-0095" role="doc-biblioentry"><span class="author"><span class="familyName">Sotgiu</span>, <span class="givenNames">S.</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Pugliatti</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Sotgiu</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Sanna</span></span>, and <span class="author"><span class="givenNames">G.</span> <span class="familyName">Rosati</span></span>. <span class="pubYear" data-year="2003">2003</span>. <span class="articleTitle">Does the &#x201c;hygiene hypothesis&#x201d; provide an explanation for the high prevalence of multiple sclerosis in Sardinia?</span> <span class="journalTitle">Autoimmunity</span> <span class="vol">36</span>:<span class="pageFirst">257</span>&#x2013;<span class="pageLast">260</span>.</span></li><li class="bib" id="brb3362-bib-0096"><span class="citation" data-type="journal" id="brb3362-cit-0096" role="doc-biblioentry"><span class="author"><span class="familyName">Stadelmann</span>, <span class="givenNames">C.</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Ludwin</span></span>, <span class="author"><span class="givenNames">T.</span> <span class="familyName">Tabira</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Guseo</span></span>, <span class="author"><span class="givenNames">C. F.</span> <span class="familyName">Lucchinetti</span></span>, <span class="author"><span class="givenNames">L.</span> <span class="familyName">Leel&#x2010;Ossy</span></span>, et&#xa0;al. <span class="pubYear" data-year="2005">2005</span>. <span class="articleTitle">Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis</span>. <span class="journalTitle">Brain</span> <span class="vol">128</span>:<span class="pageFirst">979</span>&#x2013;<span class="pageLast">987</span>.</span></li><li class="bib" id="brb3362-bib-0501"><span class="citation" data-type="journal" id="brb3362-cit-0501" role="doc-biblioentry"><span class="author"><span class="familyName">Swanton</span>, <span class="givenNames">J. K.</span></span>, <span class="author"><span class="givenNames">K.</span> <span class="familyName">Fernando</span></span>, <span class="author"><span class="givenNames">C. M.</span> <span class="familyName">Dalton</span></span>, <span class="author"><span class="givenNames">K. A.</span> <span class="familyName">Miszkiel</span></span>, <span class="author"><span class="givenNames">A. J.</span> <span class="familyName">Thompson</span></span>, <span class="author"><span class="givenNames">G. T.</span> <span class="familyName">Plant</span></span>, et&#xa0;al. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes</span>. <span class="journalTitle">J. Neurol. Neurosurg. Psychiatry</span> <span class="vol">77</span>:<span class="pageFirst">830</span>&#x2013;<span class="pageLast">833</span>.</span></li><li class="bib" id="brb3362-bib-0502"><span class="citation" data-type="journal" id="brb3362-cit-0502" role="doc-biblioentry"><span class="author"><span class="familyName">Swanton</span>, <span class="givenNames">J. K.</span></span>, <span class="author"><span class="givenNames">A.</span> <span class="familyName">Rovira</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Tintore</span></span>, <span class="author"><span class="givenNames">D. R.</span> <span class="familyName">Altman</span></span>, <span class="author"><span class="givenNames">F.</span> <span class="familyName">Barkhof</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Filippi</span></span>, et&#xa0;al. <span class="pubYear" data-year="2007">2007</span>. <span class="articleTitle">MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study</span>. <span class="journalTitle">Lancet Neurol.</span> <span class="vol">6</span>:<span class="pageFirst">677</span>&#x2013;<span class="pageLast">686</span>.</span></li><li class="bib" id="brb3362-bib-0097"><span class="citation" data-type="journal" id="brb3362-cit-0097" role="doc-biblioentry"><span class="author"><span class="familyName">Sweetser</span>, <span class="givenNames">M. T.</span></span>, <span class="author"><span class="givenNames">K. T.</span> <span class="familyName">Dawson</span></span>, and <span class="author"><span class="givenNames">C.</span> <span class="familyName">Bozic</span></span>. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Case reports of PML in patients treated for psoriasis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">369</span>:<span class="pageFirst">1082</span>.</span></li><li class="bib" id="brb3362-bib-0098"><span class="citation" data-type="journal" id="brb3362-cit-0098" role="doc-biblioentry"><span class="author"><span class="familyName">Trapp</span>, <span class="givenNames">B. D.</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Peterson</span></span>, <span class="author"><span class="givenNames">R. M.</span> <span class="familyName">Ransohoff</span></span>, <span class="author"><span class="givenNames">R.</span> <span class="familyName">Rudick</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Mork</span></span>, and <span class="author"><span class="givenNames">L.</span> <span class="familyName">Bo</span></span>. <span class="pubYear" data-year="1998">1998</span>. <span class="articleTitle">Axonal transection in the lesions of multiple sclerosis</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">338</span>:<span class="pageFirst">278</span>&#x2013;<span class="pageLast">285</span>.</span></li><li class="bib" id="brb3362-bib-1002"><span class="citation" data-type="other" id="brb3362-cit-1002" role="doc-biblioentry"><span class="groupName">TYSABRI<sup>&#xae;</sup> (natalizumab): PML Incidence in Patients Receiving TYSABRI</span> ( December <span class="pubYear" data-year="2014">2014</span>). Medical Information, <a class="email" href="mailto:medinfo@biogenidec.com">medinfo@biogenidec.com</a>, <span class="url"><a class="urlAnchor" href="http://medinfo.biogenidec.com" target="_blank">http://medinfo.biogenidec.com</a></span>.</span></li><li class="bib" id="brb3362-bib-0099"><span class="citation" data-type="journal" id="brb3362-cit-0099" role="doc-biblioentry"><span class="author"><span class="familyName">Tzartos</span>, <span class="givenNames">J. S.</span></span>, <span class="author"><span class="givenNames">M. A.</span> <span class="familyName">Friese</span></span>, <span class="author"><span class="givenNames">M. J.</span> <span class="familyName">Craner</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Palace</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Newcombe</span></span>, <span class="author"><span class="givenNames">M. M.</span> <span class="familyName">Esiri</span></span>, et&#xa0;al. <span class="pubYear" data-year="2008">2008</span>. <span class="articleTitle">Interleukin&#x2010;17 production in central nervous system&#x2010;infiltrating T cells and glial cells is associated with active disease in multiple sclerosis</span>. <span class="journalTitle">Am. J. Pathol.</span> <span class="vol">172</span>:<span class="pageFirst">146</span>&#x2013;<span class="pageLast">155</span>.</span></li><li class="bib" id="brb3362-bib-0100"><span class="citation" data-type="journal" id="brb3362-cit-0100" role="doc-biblioentry"><span class="author"><span class="familyName">Weber</span>, <span class="givenNames">F.</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Janovskaja</span></span>, <span class="author"><span class="givenNames">T.</span> <span class="familyName">Polak</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Poser</span></span>, and <span class="author"><span class="givenNames">P.</span> <span class="familyName">Rieckmann</span></span>. <span class="pubYear" data-year="1999">1999</span>. <span class="articleTitle">Effect of interferon beta on human myelin basic protein&#x2010;specific T&#x2010;cell lines: comparison of IFNbeta&#x2010;1a and IFNbeta&#x2010;1b</span>. <span class="journalTitle">Neurology</span> <span class="vol">52</span>:<span class="pageFirst">1069</span>&#x2013;<span class="pageLast">1071</span>.</span></li><li class="bib" id="brb3362-bib-0101"><span class="citation" data-type="journal" id="brb3362-cit-0101" role="doc-biblioentry"><span class="author"><span class="familyName">Weinshenker</span>, <span class="givenNames">B. G.</span></span> <span class="pubYear" data-year="1996">1996</span>. <span class="articleTitle">Epidemiology of multiple sclerosis</span>. <span class="journalTitle">Neurol. Clin.</span> <span class="vol">14</span>:<span class="pageFirst">291</span>&#x2013;<span class="pageLast">308</span>.</span></li><li class="bib" id="brb3362-bib-0102"><span class="citation" data-type="journal" id="brb3362-cit-0102" role="doc-biblioentry"><span class="author"><span class="familyName">Weinshenker</span>, <span class="givenNames">B. G.</span></span>, <span class="author"><span class="givenNames">B.</span> <span class="familyName">Bass</span></span>, <span class="author"><span class="givenNames">G. P.</span> <span class="familyName">Rice</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Noseworthy</span></span>, <span class="author"><span class="givenNames">W.</span> <span class="familyName">Carriere</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Baskerville</span></span>, et&#xa0;al. <span class="pubYear" data-year="1989">1989</span>. <span class="articleTitle">The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability</span>. <span class="journalTitle">Brain</span> <span class="vol">112</span>(<span class="issue">Pt 1</span>):<span class="pageFirst">133</span>&#x2013;<span class="pageLast">146</span>.</span></li><li class="bib" id="brb3362-bib-0103"><span class="citation" data-type="journal" id="brb3362-cit-0103" role="doc-biblioentry"><span class="author"><span class="familyName">Weinstock&#x2010;Guttman</span>, <span class="givenNames">B.</span></span>, <span class="author"><span class="givenNames">R. M.</span> <span class="familyName">Ransohoff</span></span>, <span class="author"><span class="givenNames">R. P.</span> <span class="familyName">Kinkel</span></span>, and <span class="author"><span class="givenNames">R. A.</span> <span class="familyName">Rudick</span></span>. <span class="pubYear" data-year="1995">1995</span>. <span class="articleTitle">The interferons: biological effects, mechanisms of action, and use in multiple sclerosis</span>. <span class="journalTitle">Ann. Neurol.</span> <span class="vol">37</span>:<span class="pageFirst">7</span>&#x2013;<span class="pageLast">15</span>.</span></li><li class="bib" id="brb3362-bib-0104"><span class="citation" data-type="journal" id="brb3362-cit-0104" role="doc-biblioentry"><span class="author"><span class="familyName">Williams</span>, <span class="givenNames">R.</span></span>, <span class="author"><span class="givenNames">A. S.</span> <span class="familyName">Rigby</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Airey</span></span>, <span class="author"><span class="givenNames">M.</span> <span class="familyName">Robinson</span></span>, and <span class="author"><span class="givenNames">H.</span> <span class="familyName">Ford</span></span>. <span class="pubYear" data-year="1995">1995</span>. <span class="articleTitle">Multiple sclerosis: it epidemiological, genetic, and health care impact</span>. <span class="journalTitle">J. Epidemiol. Community Health</span> <span class="vol">49</span>:<span class="pageFirst">563</span>&#x2013;<span class="pageLast">569</span>.</span></li><li class="bib" id="brb3362-bib-0105"><span class="citation" data-type="journal" id="brb3362-cit-0105" role="doc-biblioentry"><span class="author"><span class="familyName">Wingerchuk</span>, <span class="givenNames">D. M.</span></span> <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Smoking: effects on multiple sclerosis susceptibility and disease progression</span>. <span class="journalTitle">Therapeut. Advan. Neurol. Dis.</span> <span class="vol">5</span>:<span class="pageFirst">13</span>&#x2013;<span class="pageLast">22</span>.</span></li><li class="bib" id="brb3362-bib-0106"><span class="citation" data-type="journal" id="brb3362-cit-0106" role="doc-biblioentry"><span class="author"><span class="familyName">Wolinsky</span>, <span class="givenNames">J. S.</span></span> <span class="pubYear" data-year="1995">1995</span>. <span class="articleTitle">Copolymer 1: a most reasonable alternative therapy for early relapsing&#x2010;remitting multiple sclerosis with mild disability</span>. <span class="journalTitle">Neurology</span> <span class="vol">45</span>:<span class="pageFirst">1245</span>&#x2013;<span class="pageLast">1247</span>.</span></li><li class="bib" id="brb3362-bib-0107"><span class="citation" data-type="journal" id="brb3362-cit-0107" role="doc-biblioentry"><span class="author"><span class="familyName">Wu</span>, <span class="givenNames">C.</span></span>, <span class="author"><span class="givenNames">N.</span> <span class="familyName">Yosef</span></span>, <span class="author"><span class="givenNames">T.</span> <span class="familyName">Thalhamer</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Zhu</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Xiao</span></span>, <span class="author"><span class="givenNames">Y.</span> <span class="familyName">Kishi</span></span>, et&#xa0;al. <span class="pubYear" data-year="2013">2013</span>. <span class="articleTitle">Induction of pathogenic TH17 cells by inducible salt&#x2010;sensing kinase SGK1</span>. <span class="journalTitle">Nature</span> <span class="vol">496</span>:<span class="pageFirst">513</span>&#x2013;<span class="pageLast">517</span>.</span></li><li class="bib" id="brb3362-bib-0108"><span class="citation" data-type="journal" id="brb3362-cit-0108" role="doc-biblioentry"><span class="author"><span class="familyName">Wucherpfennig</span>, <span class="givenNames">K. W.</span></span>, and <span class="author"><span class="givenNames">J. L.</span> <span class="familyName">Strominger</span></span>. <span class="pubYear" data-year="1995">1995</span>. <span class="articleTitle">Molecular mimicry in T cell&#x2010;mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein</span>. <span class="journalTitle">Cell</span> <span class="vol">80</span>:<span class="pageFirst">695</span>&#x2013;<span class="pageLast">705</span>.</span></li><li class="bib" id="brb3362-bib-0109"><span class="citation" data-type="journal" id="brb3362-cit-0109" role="doc-biblioentry"><span class="author"><span class="familyName">Yong</span>, <span class="givenNames">V. W.</span></span> <span class="pubYear" data-year="2004">2004</span>. <span class="articleTitle">Immunopathogenesis of multiple sclerosis</span>. <span class="journalTitle">Contin. Lifelong Learn. Neurol.</span> <span class="vol">10</span>:<span class="pageFirst">11</span>&#x2013;<span class="pageLast">27</span>.</span></li><li class="bib" id="brb3362-bib-0110"><span class="citation" data-type="journal" id="brb3362-cit-0110" role="doc-biblioentry"><span class="author"><span class="familyName">Yong</span>, <span class="givenNames">V. W.</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Chabot</span></span>, <span class="author"><span class="givenNames">O.</span> <span class="familyName">Stuve</span></span>, and <span class="author"><span class="givenNames">G.</span> <span class="familyName">Williams</span></span>. <span class="pubYear" data-year="1998">1998</span>. <span class="articleTitle">Interferon beta in the treatment of multiple sclerosis: mechanisms of action</span>. <span class="journalTitle">Neurology</span> <span class="vol">51</span>:<span class="pageFirst">682</span>&#x2013;<span class="pageLast">689</span>.</span></li><li class="bib" id="brb3362-bib-0111"><span class="citation" data-type="journal" id="brb3362-cit-0111" role="doc-biblioentry"><span class="author"><span class="familyName">Yousry</span>, <span class="givenNames">T. A.</span></span>, <span class="author"><span class="givenNames">E. O.</span> <span class="familyName">Major</span></span>, <span class="author"><span class="givenNames">C.</span> <span class="familyName">Ryschkewitsch</span></span>, <span class="author"><span class="givenNames">G.</span> <span class="familyName">Fahle</span></span>, <span class="author"><span class="givenNames">S.</span> <span class="familyName">Fischer</span></span>, <span class="author"><span class="givenNames">J.</span> <span class="familyName">Hou</span></span>, et&#xa0;al. <span class="pubYear" data-year="2006">2006</span>. <span class="articleTitle">Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy</span>. <span class="journalTitle">N. Engl. J. Med.</span> <span class="vol">354</span>:<span class="pageFirst">924</span>&#x2013;<span class="pageLast">933</span>.</span></li><li class="bib" id="brb3362-bib-0112"><span class="citation" data-type="journal" id="brb3362-cit-0112" role="doc-biblioentry"><span class="author"><span class="familyName">Zettl</span>, <span class="givenNames">U. K.</span></span>, <span class="author"><span class="givenNames">O.</span> <span class="familyName">Stuve</span></span>, and <span class="author"><span class="givenNames">R.</span> <span class="familyName">Patejdl</span></span>. <span class="pubYear" data-year="2012">2012</span>. <span class="articleTitle">Immune&#x2010;mediated CNS diseases: a review on nosological classification and clinical features</span>. <span class="journalTitle">Autoimmun. Rev.</span> <span class="vol">11</span>:<span class="pageFirst">167</span>&#x2013;<span class="pageLast">173</span>.</span></li></ul></section></article></body>
</html>